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ABSTRACT 
DYSREGULA nON OF MICRORNA EXPRESSION IN ACQUIRED 
ENDOCRINE-RESISTANT BREAST CANCER 
Tissa T. Manavalan 
September 20, 2012 
MicroRNAs (miRNAs) regulate gene expression at the post-transcriptional 
level by repressing translation or stimulating mRNA degradation. In this study, I 
tested the hypothesis that miRNAs are differentially expressed in antiestrogen-
sensitive MCF-7 versus -resistant L Y2 human breast cancer cells. Microarray 
analyses identified 97 miRNAs that are differentially expressed between two estrogen 
receptor alpha (ERa) -positive human breast cancer cell lines: endocrine-sensitive 
MCF-7 versus -resistant L Y2 cells under basal conditions. Opposite expression of 
miRs-lOa, -21, -22, -12Sb, -181, -200a, -200b, -200c, -221, and -222 was confirmed 
between MCF-7 and L Y2 cells. The ER antagonist ICI 182,780 (fulvestrant or 
Faslodex) generally blocked the effect of estradiol E2 and 4-hydroxytamoxifen (4-
OHT) regulated miRs, i.e .. , miR-lOa, miR-21, miR-22, miR-200a, miR-221, and miR-
222, indicating that these responses in MCF-7 cells are ER-mediated. Time-
dependent variation in basal (ethanol, the vehicle), E2, and 4-0HT regulation of the 
top 8 miRNAs was detected in MCF-7 cells. Bioinformatic analyses to impute the 
biological significance of the identified miRNAs by identifying their computationally 
predicted target genes in the human genome using TargetScan, Pic Tar, and the Sanger 
v 
miRBase Targets databases was performed. Thirty six putative mRNA targets were 
identified. Agreement in the direction of anticipated regulation was detected for 12 
putative targets. These miRNAs showing opposite expression between these two 
breast cancer cell lines may be involved in endocrine resistance. 
MiR-200 family includes two clusters i.e. miR-200 aJ200bl 429 and miR-
200cl141 encoded on chromosome 1 and chromosome 12, respectively. Lower miR-
200a, miR-200 band miR-200c expression was observed in estrogen-independent 
LCC1 and endocrine-resistant LCC2, LCC9, and LY2 compared to the parental, 
endocrine-sensitive MCF-7 human breast cancer cell line. ZEB 1 protein was found to 
be expressed in endocrine-resistant LY2 cells but not in endocrine-sensitive MCF-7 
cells. L Y2 cells did not express E-cadherin, a ZEB 1 target which is a marker for 
epithelial phenotype. This is the first demonstration that L Y2 cells have undergone 
EMT as part of their endocrine-resistant phenotype. Concomitant with miR-200 
decrease, there was an increase in ZEB 1 mRNA expressIOn m L Y2 cells. 
Overexpression of miR-200b or miR-200c in LY2 cells changed the cellular 
morphology from a mesenchymal to an epithelial appearance and sensitized cells to 
inhibition by 4-0HT and fulvestrant. These studies indicate that reduced expression 
of miR-200 and a corresponding increase in ZEB 1 protein is an indicator of 
endocrine-resistance in breast cancer cells. 
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CHAPTER I: INTRODUCTION TO BREAST CANCER 
BREAST CANCER AND ESTROGEN SIGNALING 
Breast cancer is the leading non-cutaneous form of cancer that is diagnosed in 
women of the United States [I]. According to the American Cancer Society, it is 
estimated that in 20 II about 230,000 women will be diagnosed with invasive breast 
cancer and approximately 39,520 women are expected to die from breast cancer [2] 
(http://www.cancer.orglResearch/CancerFactsFigureslBreastCancerFactsFigureslbrea 
st-cancer-facts-and-figures-20l1-2012). Although the highest incidence of breast 
cancer is seen on non-hispanic white women, death due to this cancer is highest in 
African-American women because they have triple-negative breast cancer (TNBC). 
In TNBC, which is the most aggressive form of breast cancer, cells do not express 
estrogen receptor (ER), progesterone receptor (PR) or the epidermal growth factor 
receptor (HER2/neu/erbB2). In the last two decades, the incidence rates for breast 
cancer in women over 50 has declined by 2 % due to early detection and better 
therapy, including the use of the antiestrogen tamoxifen. 
http://www.breastcancer.org/symptoms/understand_bc/statistics.jsp . 
The breast tissue is composed of milk producing lobules and ducts that 
connect lobules to the nipple. The luminal epithelial cells that line the ducts of the 
breast are regulated by steroid hormones, such as estrogens and progesterone and 
peptide hormones i.e. Prolactin, Oxytocin. Estrogens are steroid hormones produced 
by the ovary. The three forms of estrogen produced in the ovary are Estrone (E 1), 
Estradiol (E2) and Estriol (E3). EJ is the major form of estrogen in postmenopausal 
women, E2 is the predominant form of estrogen in pre-menopausal women and E3 is 
primarily synthesized in pregnancy. Estrogens promote cell replication by binding to 
their receptors, estrogen receptors alpha (ERa) and beta (ERP) that mediate the 
subsequent recruitment of coregulators, chromatin remodeling complexes, and RNA 
polymerase leading to transcription of estrogen responsive genes [3]. The two modes 
of signaling through the ER include genomic and non genomic. 
Genomic ER signaling - Binding of E2 to ER induces a conformation change to the 
ER leading to its activation and binding to DNA sequences called estrogen response 
elements (EREs). This is the classic or genomic mode of estrogen signaling. 
Alternatively, the E2-ER complex may interact with DNA indirectly by a 'tethering' 
mechanism involving direct interaction of ER with transcription factors including AP-
I, Sp I or NF-KB [4]. Depending on the type of transcriptional coregulators 
associated with ER, the E2-ER complex can have different effects [5,6]. For example, 
E2-ER binds to the ERE of the NRF-l gene in MCF-7 cells and recruits API 
coactivator and RNA polymerase to increase the expression of TFAM mitochondrial 
gene [7]. Ligand independent ER signaling involves protein kinases that 
phosphorylate and activate ER. 
Non-genomic ER signaling - In addition to genomic ER signaling a small percent of 
total cellular ERa that are localized in the plasma membrane (PM) can initiate rapid 
activation of intracellular phosphorylation cascades mediated by extracellular signal 
regulated kinases 1/2 (ERK1I2) and phosphoinositide 3-kinase (PI3K or AKT) [8,9]. 
This rapid E2-initiated cascade is referred to as "membrane-initiated" or "non-
genomic" ER signaling and is independent of gene transcription, although 'non-
2 
genomic' estrogen activation of signaling pathways can stimulate gene transcription 
in breast cancer cells [10]. 
GPR30/ GPER: In addition to ERa, there is a plasma membrane-bound estrogen 
receptor that is a G-coupled protein receptor (GPR30IGPER) [11,12]. Filardo et al. 
have shown that E2 can activate the MAPK signaling cascade via binding to GPR30 
leading to transcription of cell proliferative genes [13] . ER antagonists ICI 182, 780 
and 4-0HT were found to activate GPR30 and mediate MAPK signaling [14]. 
In addition, ligand activated membrane ERa can phosphorylate and activate 
key signaling molecules including Epidermal Growth Factor Receptor (EGFR), c- src, 
Shc and p85a regulatory subunit of MAPK [15-17]. Although this mechanism is 
independent of E2-mediated transcription, the activation of signaling pathways may 
affect downstream molecules, subsequently leading to nuclear ER activity and also 
induce transcription of E2-responsive genes [18]. Thus there is cross-talk between 
growth factor receptor pathways and genomic ER signaling [17]. 
ENDOCRINE THERAPIES FOR THE TREATMENT OF BREAST CANCER 
Estrogens are natural ligands of ER. Blocking estrogen-mediated tumor 
growth has been the mode of breast cancer treatment for many years. Endocrine 
therapies either target ERa action or block estrogen synthesis. Antiestrogens (e.g., 
Tamoxifen (TAM) and Raloxifene (RAL» function by binding to the ER and 
blocking its transcriptional activity. ICI 46,474 (now known as TAM) was originally 
developed by Imperial Chemical Industries (lCI) Ltd. Pharmaceuticals Division [19]. 
It was developed by a group of scientists that included Arthur Walpole, Dora 
Richardson and Michael J.K Harper. Although initial studies focused on its role as a 
contraceptive drug, it was Walpole who later on suggested its use as an antiestrogen. 
3 
He identified that TAM acts as an estrogen in the mouse vagina while it is an 
antiestrogen in rat vaginal epithelium and uterus [20,21]. Walpole also suggested that 
TAM may inhibit tumor formation in the breast. After his death in 1977, significant 
studies on TAM's role as a SERM (Selective Estrogen Receptor Modulator) as well 
as an antitumor agent was investigated by Craig V. Jordan [22-25] . 
It was in 1977 that TAM was approved by the FDA to be used clinically as an 
antiestrogen in the United States. Since then, TAM, a non-steroidal antiestrogen, has 
been widely used for the prevention and treatment of ERa-positive breast cancer 
[26,27]. TAM has cell-type-specific mixed agonist/antagonist activity, and is thereby 
classified as a SERM [28]. SERMs are classified according to its structure, which are 
more or less similar to E2. TAM is a triphenylethylene which is metabolized in the 
liver to its active form 4-0HT by the cytochrome P450 enzyme CYP2D6. In the 
breast, 4-0HT acts as an ER antagonist and competes with E2 for binding to the ER. 
For over 30 years, TAM has been the 'gold standard' for the treatment of breast 
cancer in pre-menopausal women [29]. One of the disadvantages of TAM is that 
women on TAM therapy have an increased risk of uterine cancer due to its agonist 
activity in the uterus [30]. 
RAL and arzoxifene are benzothiophenes. RAL avoids some of the side 
effects associated with TAM due to its antagonist activity in both breast and uterus. 
RAL was first approved in 1997 by the FDA to be used in the treatment of 
osteoporosis in post-menopausal women [31]. It was subsequently demonstrated to 
prevent recurrent disease and primary breast cancer by a number of clinical trials [32]. 
The RUTH (Raloxifene Use For The Heart) is a significant trial that demonstrated the 
use of RAL in the treatment of osteoporosis in post-menopausal women who had 
cardiovascular disease [33]. The trial showed that RAL is effective not only in the 
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treatment of osteoporosis but also for ER-positive breast cancer. Results of the STAR 
(Study of Tamoxifen and Raloxifene) trial that was published in 2006 further 
confirmed the role of RAL in the treatment of osteoporosis as well as invasive breast 
cancer in women [34]. 
Another class of antiestrogens used in the treatment of breast cancer is called 
Selective Estrogen Receptor Downregulators (SERD) with the prototype fulvestrant. 
It is a SERD because it binds the ligand binding domain (LBD) noncovalently, and 
targets ERa to the 26S proteasome for degradation [35]. 
Aromatase inhibitors (AIs) are a class of antiestrogens that block estrogen 
synthesis [36]. In post-menopausal women, estrogens are no longer synthesized by 
the ovaries. However estrogens are synthesized from either locally produced or 
adrenal androgenic precursors (e.g. DHEA or Dehydroepiandrosterone, DHEA-
sulphate) in peripheral tissues including adipose tissue, brain, skin, bone, 
endometrium, and breast [37]. In these tissues, the enzyme aromatase (CYP 19A1) 
catalyzes the conversion of androgens, (i.e., testosterone and androstenedione) to 
estrogens (i.e., E, and E2, respectively). The three most commonly used AIs are 
letrozole, anastrozole and exemestane. AIs have been shown to be more effective 
than TAM in promoting disease-free survival in post-menopausal women [38]. 
Exemestane is a steroidal AI that bind to the substrate-binding site of aromatase 
enzyme and irreversibly inhibits its action [39]. Letrozole and Anastrozole are non-
steroidal AIs that bind reversibly to the substrate binding site of the aromatase 
enzyme [4]. Unlike TAM, AIs do not increase the risk of endometriosis and 
thromboembolism [40]. However AIs increase osteoporosis and fractures along with 
side effects such as hot flashes and headaches. The use of AIs is limited by 
musculoskeletal pain which some breast cancer survivors find intolerable [41]. 
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MECHANISMS OF ENDOCRINEffAMOXIFEN-RESISTANCE 
Although hundreds of thousands of women are alive today because TAM 
prevents breast cancer recurrence [42], the majority of tumors that initially respond to 
TAM develop resistance. It is estimated that 40% of the women who receive adjuvant 
hormonal therapy acquire endocrine resistance [43,44]. The mechanisms of acquired 
endocrine/TAM- resistance remain to be fully elucidated despite intense study by 
many labs over the past 25 years [45] 
Loss of ERa and aberrant expression of coregulators contribute to endocrine-
resistance- Acquired endocrine resistance, which occurs after a woman was initially 
successfully treated on TAM, was originally thought to be due to loss of ERa 
expression. Mechanisms involved in the loss of ERa expression include activation of 
EGFR and MAPK signaling [46,47], methylation of ERa promoter [48] and hypoxia 
[49]. However, ERa was found to be lost in only 15-20% of TAM-resistant cancers, 
suggesting other mechanisms for the development of endocrinelTAM-resistance [50]. 
Recent studies show that a variant of ERa called ERa36 is expressed in tumors that 
are not responsive to TAM [51]. Another variant of ERa called ERa46 was found to 
be decreased in TAM-resistant breast cancer [52]. 
Other factors that playa role in the development of endocrinelTAM-resistance 
include altered expression of coregulators [53-56]. For example, AlB 1 (also known 
as SRC-3 or NCoA-3), a nuclear coactivator is overexpressed in breast tumors and is 
associated with increased ERa mediated transcription [56] and reduced TAM-
responsiveness in patients [57]. On the other hand, reduced expression of Nuclear 
receptor co-repressor (NCoR) was observed in a mouse model of human breast cancer 
and correlated with TAM-resistance [58]. Low NCoR is associated with a shorter 
disease-free survival and is used as predictor of TAM-resistance in ERa-positive 
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breast cancer [59]. Increased expression of AP-I, Sp 1 and NF-KB transcription 
factors have been associated with endocrine resistance [60-62]. TAM-liganded ERa 
acts as an antagonist and increases AP-l and NF-kB transcriptional activities in MCF-
7 breast cancer cells [63]. TAM-liganded ERJ3 was found to act as an agonist and 
induce AP-l regulated gene transcription in MCF-7 and MDA-MB-453 breast cancer 
and Ishikawa endometrial cancer cells transfected with an ERJ3 expression plasmid 
[63]. This leads to enhanced cell proliferation and growth, resulting in TAM-
resistance. Increased NF-KB transcriptional response was reported in TAM- resistant 
and ERBB2-positive cell lines, MCF-7/HER2 and BT474 [62]. The study showed 
that the increase in NFkB transcriptional response was reversed by the NF-kB 
inhibitor Parthenolide leading to better response to TAM. The study also showed that 
the increased TAM-responsiveness in these cells was due to enhanced recruitment of 
the corepressor NCoR to the TAM-ER complex upon treatment with the inhibitors. 
Post-translational modifications of ERa contributes to endocrine resistance -
Posttranslational modifications such as phosphorylation, sumoylation and acetylation 
can alter the conformation of ERa such that it affects its ligand binding properties and 
interaction with proteins such as coregulators [64-66]. Phosphorylation of ERa takes 
place mainly by activation of kinase pathways such as protein kinase A (PKA), 
MAPK and Src pathways [67-69]. Some of the phosphorylation sites within ERa that 
can alter the response of cells to TAM include Ser102/4/6, Ser 118 and Ser 305 [66]. 
The Ser 118 residue on ERa can be phoshorylated by pathways such as MAPK, 
PI3K, CDK7 and IKKa [70-72] . E2 or EGF can induce the MAPK pathway and thus 
phosphorylate Ser118 leading to enhanced ERa activation [73]. Phosphorylation of 
ERa on Ser118 by MAPK was found to reduce its affinity for TAM [72]. ERa that is 
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phosphorylated at Ser-118 was also found to have decreased DNA binding capacity 
when bound to TAM. Another consequence of phosphorylation of ERa at Ser 118 is 
its altered interaction with coactivator AIB I [72]. Phosphorylation of ERa at Ser305 
by PKA has been shown to result in TAM resistance by altering the interaction of 
ERa with coactivator NCoA-1 (also known as SRC-I), and promote transcription by 
TAM [74-76]. P21-activated protein kinase-l (Pakl) phosphorylates ERa at Ser305. 
This leads to transactivation of ERa independent of ligand binding and increases 
ERa-mediated transcriptional activity. As a result there is reduced responsiveness of 
tumors to TAM [77,78]. Hence expression of Pak 1 is considered as a poor prognostic 
marker for TAM resistance. 
Altered glycosylation is an early step in carcinogenic transformation [79] and 
yet is an understudied field of knowledge regarding modification of ERa and other 
proteins that can move between the plasma membrane and nuclear compartment. 
Glycosylation of ERa at the hydroxyl group of its Ser or Thr residues has been 
reported [80,81]. O-linked N-acetyl glucosamine (O-GlcNAC) residues were 
identified on ERa that was isolated from bovine calf uteri and insect cells expressing 
mouse ERa [80]. The Thr575 residue on the C-terminal fragment of ERa was 
identified as a major site of glycosylation site in these ERa. Additional glycosylation 
sites were later identified on Ser 10 and Thr50 of mouse ERa [81]. However these 
modifications were not found to alter the DNA-binding properties of ERa. 
Acetylation of transcription factors by histone acetyl transferases (HATs) such as 
p300, CBP and P/CAF makes the DNA accessible to nuclear coregulators [82]. 
Acetylation of ERa by p300 at Lys residues 266 and 268 in its hinge/ ligand binding 
domain was reported by Mi et al. [83]. Their study demonstrated that acetylation of 
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ERa did not modify its localization or ability to bind E2 or coregulators. However, 
acetylation increased ERa's DNA binding properties and transactivation. Contrary to 
this observation, mutation of Lys302 and 303 residues of ERa to Arg enhanced its 
activation by E2 [84]. They found that acetylation is specific to Lys302 and 303 
residues in the hinge region of ERa. This indicates an inhibitory effect of acetylation 
on the sensitivity of ERa to ligands. Mutation of Lys residues could thus contribute 
to development of breast cancer. Interestingly, an ERa K303R mutation has been 
reported in breast cancer patients with atypical hyperplasia [85] 
Sumoylation is a post- translational modification involving addition of SUMO 
(small ubiquitin-like modifier) moieties to proteins. SUMOylation is increased in 
carcinogenesis [86]. ERa is sumoylated by (SUMO)-l, at the Lys residues in the 
hinge region [87]. Sumoylation enhanced ERa transcriptional activity. Proteins 
PIAS 1 and PIAS3 were found to stimulate sumoylation of ERa in the presence of 
ligands, e.g., E2 and TAM [87]. This would be expected to increase ERa turnover. 
Using mutation studies involving substitution of Lys residues in the hinge region with 
Arg, the authors observed that there was an inhibition of sumoylation and reduced 
ERa transcriptional activity. Thus posttranslational modifications of ERa alter its 
transcriptional activity as well as interaction with coregulators. 
Aberrant growth factor receptors and cytoplasmic signaling contribute to endocrine 
resistance 
Role of Receptor Tyrosine Kinases (RTK) - Enhanced RTK signaling mediated by 
growth factor overexpression or intrinsic activation has a role in endocrine resistance. 
Further, overexpression of EGFR, insulin like growth factor receptor (lGFR) and the 
mutant human epidermal growth factor receptor (HER-2/neu or ERBB2) contribute to 
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endocrine/TAM-resistance because they activate cell survival/proliferation responses 
independent of estrogen-ER activity [88-91]. 
Endocrine resistance also involves activation of the intracellular protein kinase 
pathways, (e.g. the MAPK and the PI3K) that are downstream of plasma membrane-
initiated EGFR, IGFR and ERBB2 signaling [89,92]. Deregulation of these pathways 
could be due to genetic modifications such as mutation of PTEN, a tumor suppressor 
that inhibits PI3K, or due to amplification of ERBB2 [64,93,94]. The mechanism of 
ERBB2 overexpression in endocrine resistance is not fully understood. However it is 
proposed that the intrinsic activation of ERBB2 and subsequent activation of the 
MAPK pathway that leads to phosphorylation of ERa at Ser118 results in its ligand-
independent activation [94-96]. This would lead to non-responsiveness of cells to 
TAM-mediated repression of ERa-mediated transcription. Another mechanism of 
antiestrogen-resistance in ERBB2 overexpressing cells is the impaired recruitment of 
transcriptional corepressors such as NCoR and SMRT by TAM-occupied ERa [94]. 
As a result there is reduced responsiveness of ERBB2-overexpressing cells to TAM. 
This was seen in ERBB2-expressing tumor samples. 
Role of cell cycle modulators - Aberrant expression of cell cycle regulators that are 
targets of antiestrogens can lead to endocrine resistance [97]. Overexpression of 
MYC, cyclin E1 or cyclin 01, inactivation of the retinoblastoma (Rb) tumor 
suppressor, or the decreased expression of cyclin-dependent kinase (CDK) inhibitors 
p21 and p27 lead to loss of antiestrogen-responsiveness [98-102]. c-Myc, a nuclear 
transcription factor has mitogenic effects similar to E2 and is, in fact, an immediate 
early gene product stimulated by E2-ERa [103]. MYC promotes cell cycle 
progression by regulating cell cycle modulators (e.g. p21 and p27) [104]. MYC 
overexpression has been shown to promote TAM-resistance by suppressing the 
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expression of CDKN1A that encodes p21 which is a repressor of cell cycle regulators 
cyclin-cdk2 [105]. This relief of repression of cyclin E1 CDK2 complexes by p21 
results in enhanced growth rate in response to TAM. Along with CDK2, Cyclin EI 
promotes entry of cells into the S-phase of the cell cycle [97]. Cyclin DI 
overexpression also leads to increased tumor growth in response to TAM [106]. This 
is due to enhanced cyclin DI binding to ERa through STAT3, thus activating 
ERa. TAM was found to enhance binding of ERa to STA T3 in the presence of 
cyclin DI, thus promoting tumor growth. Overexpression of MYC and Cyclin DI 
and Cyclin EI has also been reported in patients with breast cancer [107]. 
Loss of Rb function has also been linked to endocrine resistance [102]. Rb is a 
critical regulator of cell growth [108]. Inactivation of Rb function due to 
phosphorylation has been reported in breast cancer [109]. This loss of function is 
associated with aberrant cyclinlCDK activity. Other factors that can result in loss of 
Rb function in breast cancer includes mutation and epigenetic silencing [110]. 
Aberrant Rb pathway function has also been reported in ER-negative breast cancer 
and is used as a predictor of poor response to TAM therapy [ III ]. 
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CHAPTER II: SIGNIFICANCE OF MICRORNA EXPRESSION IN 
ENDOCRINEff AMOXIFEN -RESISTANT BREAST CANCER 
BIOGENESIS OF MICRO RNA 
Regulation of gene expression is critical for the normal development of an 
organism. MicroRNA (miRNA) are a class of short non-coding RNA that regulate 
gene expression at the post-transcriptional and/or translational level [112]. These 
RNAs, which are 21-22 nucleotides in length, regulate a number of cellular processes 
including growth, development, differentiation, apoptosis and cell cycle [113]. 
miRNAs were first described by Lee et. al. in Caenorhabiditis elegans [114]. Today 
there are over 9200 publications listed in PubMed on miRNAs in humans, reflecting 
the interest in how these RNAs post-transcriptionally regulate protein expression and 
cell function. 
miRNAs are given a three lettered prefix depending on the species that they 
originate in i.e., hsa for homo sapiens, mmu for mouse, and so on [lIS]. If miRNAs 
originate from different genomic loci, they are assigned a numerical suffix, i.e. hsa-
miR-29b-l and hsa-miR-29b-2. miRNAs that differ by a few bases are given a 
lettered suffix of the form miR-12Sa and miR-12Sb. Those miRNAs that originate 
from opposite arms of the hairpin precursor are assigned suffixes of the type miR-
l42-Sp and miR-142-3p. miR-21 and miR-21 * refers to miRNAs that arise from the 
same hairpin precursor. An asterix in the miRNA name indicates that it is a less 
predominant form of the miRNA[ 116]. miRNA cluster arises due to gene duplication, 
e.g., the miR-200 cluster of miRNAs is located in two chromosomes, i.e., miR-200a, 
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miR-200b and miR-429 are located on chromosome 1 and miR-200c and miR-141 are 
located on chromosome 12. Each cluster is transcribed into a common precursor 
RNA. A miRNA family refers to miRNAs that arise from a common ancestor and 
whose sequences are similar e.g. miR-221 and miR-222 family. 
MiRNA are located mostly in the introns of protein coding genes [117]. In 
eukaryotes, most miRNAs are transcribed by RNA polymerase II into long transcripts 
called primary miRNA (pri-miRNA) [118]. A few miRNAs are transcribed by RNA 
pol III, e.g., miR-515-1, miR-517a, miR-517c [119]. Primary miRNA is processed 
into -70 nucleotide precursor miRNAs (pre-miRNA) by a ribonuclease III (RNase III) 
enzyme Drosha in association with an RNA binding protein DGCR8 (together called 
the Microprocessor complex). Recent studies show that some intronic miRNAs 
(mirtrons) are processed by splicing machinery instead of Drosha and DGCR8 [120], 
Pre-miRNA is then exported from the nucleus to the cytoplasm by Exportin and Ran-
GTP. In the cytoplasm, the pre-miRNA is further cleaved by RNase III Dicer along 
with RNA-binding proteins TRBP and PACT (in humans) to a mature double 
stranded miRNA. Mature miRNAs is incorporated into the RNA-induced silencing 
complex (RISC) consisting of Argonaute 2 (Ag02) and TRBP protein. The miRNA 
duplex unwinds and the RISC degrades one of the strands of the miRNA (passenger 
strand, e.g., miR-21 *) while the functional strand (guide strand, e.g., miR-21) targets 
messenger RNA (mRNA) for degradation or translational repression. According to 
miRBase (version 18, November 2011), the human genome encodes more than 1500 
human miRNAs. 
MICRO RNA FUNCTION 
MiRNAs affect mRNA stability or repress translation. The 5'UTR of miRNA 
harbours a 2-8 nucleotide seed region that binds to the 3'UTR of mRNA in a 
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complementary fashion. Perfect base pairing between the miRNA and mRNA leads 
to mRNA degradation [121]. This type of perfect complementarity between miRNA 
and the target mRNA is seen in mostly in plants and rarely in vertebrates and viral 
miRNAs. 
In most metazoans, there is mostly imperfect base pairing leading to 
translational repression. Many theories have been proposed for the repression of 
translation by miRNAs. One theory states that the AG02 protein of the miRNA-
ribonUcleoprotein (miRNP) complex (consisting of mature miRNA, Ag02 and TRBP 
protein) competes with the eIF4E elongation factor from binding to the 5' cap of 
mRNA, thus repressing translation [122]. Another study shows that the elongation 
factor eIF6 is a major target of miRNPs. The authors of this study propose that 
AG02 interacts with eIF6 and inhibits joining of the 60S ribosomal subunit to the 
40S initiation complex [123]. It has also been proposed that repression of translation 
occurs at post-initiation stages of translation due to slow elongation of mRNA 
[124,125]. Repression of mRNAs by binding of miRNPs induce deadenylation 
mediated by a glycine-tryptophan protein called GW182 and poly (A) binding protein 
(PABP) which in tum recruits deadenylase CCR4 and CAF1, and subsequently 
results in decay of mRNAs [126,127]. An alternate mechanism of repression by 
miRNA is by sequestration of mRNA in P-bodies [128]. mRNAs that undergo 
translational repression by the RISC were found to accumulate in these P-bodies 
[129]. In eukaryotes, there are two modes of mRNA decay induced by miRNAs. The 
mRNA is degraded either by 3'~ 5' exosome activity or by removal of the 5' cap 
followed by 5'~3' degradation catalyzed by XRNI [130]. 
Currently there are over 10, 000 miRNAs that have been reported in different 
organisms [131]. It is estimated that miRNAs regulate -50% of protein-coding 
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genes in the human genome [132]. MiRNA target prediction software programs have 
shown that each miRNA can have more than one mRNA target. MiRNAs have been 
shown to fine-tune the expression of genes to allow optimal expression during 
different stages of development. In humans, miRNAs exhibit tissue specific 
expression and regulate cellular processes by targeting key proteins and signaling 
networks [133]. 
REGULATION OF MICRO RNA EXPRESSION 
Role of miRNA processing proteins - MiRNA expression is regulated at different 
levels. The ratio of the ribonuclease Drosha and its binding partner DGCR8 is tightly 
regulated to ensure proper pri-miRNA processing [134]. DGCR8 stabilizes Drosha. 
Drosha in tum regulates DGCR8 levels by cleaving and thus inactivating it. Thus a 
tight feedback loop maintains the cellular DroshaJDGCR8 ratio [135]. 
A number of co-activators and co-repressors can alter Drosha activity. Transforming 
growth factor beta (TGF~) signaling and bone morphogenetic protein (BMP) and 
SMAD proteins stimulate, while the nuclear factor NF90-NF45 heterodimer 
suppresses Drosha activity [136,137]. ERa along with helicases p68 and p72, and 
Drosha have been shown to affect Drosha complex formation, thus repressing pri-
miRNA processing[ 138]. 
Defects in Exportin 5 results in accumulation of pre-miRNAs in the nucleus 
[139]. Another ribonuclease that is a key point of regulation in the miRNA 
biogenesis pathway is Dicer. Altered Dicer expression can affect processing of pre-
miRNA to mature miRNA. Dicer mutation has been reported in non-small cell lung 
cancer and prostate cancer [140,141]. It has been shown that Dicer cofactors, TRBP 
and PACT are critical in maintaining the stability of Dicer in cells [142,143]. 
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Increased phosphorylation of TRBP by MAPK signaling was found to enhance Dicer 
activity and promote miRNA processing [144]. 
Role of Ag02 proteins - After cleavage of the pre-miRNA by the ribonuclease Dicer, 
one of the strands of the mature miRNA is incorporated into the RISC by Ag02 
protein. Although the human genome encodes about 8 Ago proteins, Ag02 is the 
major protein involved in RNA cleavage and silencing. The level of Ag02 determines 
the amount of mature miRNA synthesized. Ag02 is subject to regulation at the 
transcriptional and post-transcriptional level. For example in MCF-7 breast cancer 
cells Ag02 expression is inhibited by E2 and EGF-MAPK signaling [145]. 
Regulation of miRNA transcription - A number of transcription factors have been 
shown to regulate miRNA expression. For example, p53 has been shown to increase 
the expression of miR-34 and miR-107 families [146,147]. MYC stimulates the 
expression of miR-17-92 cluster of miRNAs in lymphoma cells [147]. In neuronal 
cells, the REI Silencing Transcription Factor (REST!) inhibits transcription of miR-
124 by recruiting histone deacetylases (HDACs) and methyl CpG binding protein 
MeCP2 to the miR-124 gene promoter [148]. The transcription of primary miRNA 
transcripts have been shown to be regulated by platelet-derived epidermal growth 
factor (PDGF) and transforming- growth factor-beta (TGF-~) [149,150] 
Steroid hormone regulation of miRNA expression- Steroid hormones and their 
receptors have been reported to regulate miRNA expression in a variety of cancer cell 
lines [151-153]. Because the focus of my dissertation is the role of miRNA 
expression in endocrine resistant breast cancer, I will focus on estrogen regulation of 
miRNA expression [154,155]. E2 regulation of miRNA expression was studied by 
Cohen et. al. in adult zebrafish [156]. miR-196b and Let 7h were up-regulated, and 
miR-130c and miR-lOla were downregulated by E2 treatment in this study. Further, 
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Hoxb8a, a target of miR-196b was downregulated regulated by E2 in zebrafish. In a 
model of mammary carcinogenesis in rats, E2 was found to regulate the expression of 
miRs after 6, 12 and 18 weeks of treatment in female August Copenhagen Irish (ACI) 
rats [157]. Some of the miRNAs that were altered after E2 treatment include miR-
22*, miR-99a, miR-127, miR-499, miR-17-5p, miR-20a, and miR-92. Castellano et. 
a!. have shown that E2 upregulates the expression of miRNAs encoded by the miR-
17-92 and miR-106a-363 paralogous cluster in MCF-7 breast cancer cells [158]. 
Microarrays identified 23 miRNAs to be downregulated by E2 in MCF-7 cells [159]. 
Of these, the expression of 8 were confirmed by quantitative real time PCR (Q-PCR) 
in MCF-7, BT474, T47D and ZR-75-1 breast cancer cells. The expression of pri-
miR-21 and pri-miR-181a were also found to be regulated by E2 in MCF-7 cells. 
Another study by Cicatiello et al. identified miR-424 and miR-760 to be increased by 
E2 while miR-107, miR-570 and miR-618 were found to be decreased by E2 [160]. 
This study identified miRNA binding sites in the mRNA of E2-regulated target genes 
by global mapping. 
Work done m our laboratory has also shown that E2 regulates miRNA 
expression in MCF-7 breast cancer cells [161,162]. E2 was found to decrease miR-21 
expression which in tum increased the expression of its target genes, PDCD4 and 
BCL2. Contrary to our results, Nakshatri e. a!. reported an increase in miR-21 
expression in MCF-7 cells after treatment with lOnM E2 for 4 h [163]. However, 
others have likewise reported that E2 reduces miR-21 expression [159,164-166] A 
summary of miRNAs that are regulated by E2 was recently reviewed [167] 
Epigenetic control of miRNA expression -DNA methylation and histone 
modifications regulate miRNA expression. These mechanisms have been attributed 
to the aberrant expression of miRNAs seen in diseases such as cancer. For example, 
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hypermethylation of miR-134, miR-34b/c, miR-137, miR-342 has been reported in 
different types of cancer [168,169]. Hypomethylation of let 7a-3 has been reported in 
lung adenocarcinoma [170]. The promoter of miRNA genes e.g. miR-1 and miR-27a 
are altered by histone modification [171]. Acetylation of miR-1 gene promoter results 
in its decreased expression in lung cancer. HDAC inhibitors reversed this effect. 
MICRORNA AS ONCOGENES OR TUMOR SUPPRESSORS 
Aberrant miRNA expression has been reported in a number of diseases 
including cancer [172]. MiRNAs act as oncogenes or tumor suppressors by 
regulating the expression of genes associated with key pathways. As such, their 
expression and the regulation of their expression is of keen interest in cancer research, 
both for use as clinical biomarkers and as targets for prevention or treatment. 
MicroRNAs as tumor suppressors- miR-15a and miR-16 act as tumor suppressors by 
negatively regulating the anti-apoptotic gene BCL2. Downregulation of miR-15a and 
miR-16 has been observed in chronic lymphocytic leukemia (CML), resulting in 
increased expression of BCL2 and anti-apoptotic activity [173]. miR-34a is 
downregulated in colon, ovarian, lung and pancreatic cancers [174-176]. It targets the 
oncogene MYCN [177]. miR-34 indirectly controls p53 activation through SIRTl 
[178] . The Let-7 family of miRNAs were found to be deleted in a number of cancers 
including lung, colon and lymphomas [179,180]. They act as tumor suppressors by 
negatively regulating cell cycle regulators, CDK6 and CCND [181]; and oncogenes 
such as RAS, MYC and HMGA2 by translational repression [182,183]. 
MicroRNAs as oncogenes- One of the most important miRNAs that acts as an 
oncogene is miR-21. It has been shown to repress the expression of tumor 
suppressors such as the programmed cell death protein (PDCD4), tropomyosin 
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(TPMl), phosphatase and tensin homologue (PTEN) and maspin[184-188]. miR-21 is 
overexpressed in lung, breast, pancreatic and prostate cancer [189-191]. 
In addition to miR-21, the miR-17 -92 cluster is overexpressed in aggressive 
lung cancer and its putative targets include PTEN and RB2 [132,192]. The expression 
of miR-155 is increased in most lymphomas, e.g., miR-155 was found to be 
significantly decreased in Burkitt's lymphoma and Diffuse Large cell B-Iymphoma 
(DLBCL)[193]. It has been suggested that this overexpression of miR-155 
downregulates the expression of the transcription factor PU.1 that is important in B-
cell differentiation [194]. 
MICRO RNA EXPRESSION IN BREAST CANCER 
MiRNAs are aberrantly expressed in breast cancer [195,196]. MiRNA 
expression is either upregulated or downregulated in breast cancer cells or tumors 
when compared to normal breast tissue. miRNAs have been shown to have a role in 
tumor progression by altering the expression of oncogenes and tumor suppressors 
[197]. miRNAs promote metastasis and invasive properties of breast cancer cells. 
Expression profiling of miRNAs in solid tumors and breast tissues have identified 
miRNAs that are associated with breast cancer subtypes [198]. A few examples of 
the miRNAs that are deregulated in breast cancer include tumor suppressors such as 
Let-7, miR-125, miR-200, and the oncogenic miRs such as miR-21 and miR-155 
[199]. Downregulation of the tumor suppressor Let-7a alters the expression of its 
targets Ras and HMGA2 [200]. miR-125a and miR-125b have been shown to target 
tumor suppressors ERBB2 and ERBB3 [201]. Downregulation of Let-7a, miR-200 
and miR-205 promotes epithelial-to-mesenchyma1 transition (EMT) in breast cancer 
[202-204]. The targets of miR-200 include nuclear transcription factors ZEB 1, ZEB2; 
phospholipase C, gamma l(PLCGl) and TGF-~2 [205-207]. Other metastatic 
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promoting miRNAs that promote migration and invasion of cancer cells include miR-
lOb, miR-520c and miR-373 [208,209]. miR-lOb targets HOXDlO expression [210]. 
HOXDlO has been shown to target genes involved in angiogenesis and cell migration 
[211]. Loss of HOXD 1 0 thus promotes an invasive phenotype in breast cancer. 
The miRNAs that are oncogenic, and overexpressed in breast cancer, are miR-
21 and miR-29, miR-34, miR-155, and miR-21O [199]. MiR-21 has been shown to 
promote tumor formation by targeting PDCD4, PTEN, TPMl, and BCL2 [187,212]. 
The miR-17/92 cluster has been shown to have a dual role as a tumor suppressor and 
an oncogenic miRNA. Hossain et al. reported its role as a tumor suppressor by 
reducing the expression of the ER coactivator AlB 1 [2l3]. AlB 1 was originally 
identified as an oncogene by Myles Brown [214] and further studies have confirmed 
AIBI's role in breast cancer [215-217]. Li et at. described miR-17-5p of the 17/92 
cluster to be a metastasis promoting miRNA in breast cancer by suppressing HMG 
box-containing protein IHBPI expression [218]. HBPI is a suppressor of Wntl~­
catenin signaling. Downregulation of HBPI by miR-17-5p activates Wntl~-catenin 
signaling and thus promotes migration and invasion of MCF-7 breast cancer cells. 
Analysis of miRNA expression in breast tumors using tissue microarray 
identified a number of miRNAs that are differentially expressed in breast cancer 
tissue when compared to normal tissue, e.g., miR-lOb, miR-21, miR-145 were 
upregulated in breast cancer tissue [219]. There was also a correlation between 
miRNA expression, ER and PR status, lymph node status in these samples. In another 
study, miR-342 and miR-520g were found to be overexpressed in ER-positive and 
HER2 positive tumors when compared to normal tissue [220]. miRNA signatures 
associated with specific breast cancer cell type such as luminal and basal-like has 
been reported [198]. Let-7a, miR-21, miR-141 and miR-214 were expressed in 
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luminal cell type while miR-145 and miR-205 were associated with the myoepithelial 
cell type [221]. 
Circulating miRNAs have been detected in the blood, plasma and serum of 
breast cancer patients [222,223]. The level of plasma miRNAs was higher in breast 
cancer patients when compared to control groups [224,225]. For example miR-425*, 
Let 7c were found to be higher in the plasma of women with early stage breast cancer 
when compared to healthy controls. Higher expression of miR-lOb and miR-34 was 
found in the serum of breast cancer patients correlated with metastasis [222]. 
Systemic miR-195 and Let-7a were higher in breast cancer patients when compared to 
normal sUbjects[226]. The expression of these miRNAs also correlated with ER 
status [227]. These reports indicate that miRNAs could be valuable diagnostic 
markers in the prognosis and treatment of breast cancer. 
MICRORNAs REGULATE ERa ACTIVITY 
MiRNAs regulate ERa expression and activity. MiR-206 downregulates 
ERa mRNA and protein level in MCF-7 human breast cancer cells [228]. This study 
showed that miR-206 expression is increased in ERalERBB2-negative tumors when 
compared to ERa-positive tumor specimens. Adams et al. reported a double negative 
feedback loop between miR-206 and ERa in MCF-7 cells [229]. Another study by 
the same group reported increased miR-206 expression in MCF-7 and T47D breast 
cancer cells [230]. This increased miR-206 expression was found to suppress 
estrogenic effects in cells by decreasing the expression of ERa and coactivators such 
as NCoA-l, AIBI and GATA3 that are involved in ERa signaling. The authors 
propose that enhanced EGF signaling contributes to the loss of ERa by increasing 
miR-206 expression. This loss of ERa is one of the factors responsible for the 
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transformation of cells from luminal to a basal-type. Among the other miRNAs that 
target ERa are miR-22, miR-221 and miR-222. miR-22 degraded ERa mRNA [231]. 
The expression of this miRNA was lower in ERa-positive breast cancer cell lines 
such as MCF-7, T-47D and BT474 when compared to ERa-negative cell lines 
including MDA-MB-231 and SK-Br3 [232]. In contrast to miR-22, miR-2211222 
suppressed ERa protein and not mRNA [233]. This study identified two binding sites 
for miR-221 and miR-222 in the 3'UTR of ERa. Further, a negative feedback loop 
between miR-2211222 cluster and ERa has been reported in breast cancer cells [234]. 
miR-2211222 represses ERa, which in tum represses the expression of miR-2211222. 
Thus miR-22 11222 acts as a tumor suppressor in ERa-positive cells. However Rao et 
al. have shown that prolonged treatment of cells with E2 or fulvestrant releases miR-
221/222 from the negative feedback loop. This results in increased miR-2211222 
expression leading to enhanced cell proliferation and endocrine-resistance [235]. 
Let-7 family of miRNAs target ER-a66. There is an inverse correlation between the 
expression of Let -7 family and its target ERa-66 in breast cancer samples [236]. 
Let-7 family also targets an isoform of ERa, ERa-36 that is located in the plasma 
membrane [237]. Loss of Let-7 family was found to confer TAM-resistance due to 
increased ER-a36 and enhanced non-genomic signaling. Among the other miRNAs 
that target ERa include miR-18a, miR-18b, miR-193b and miR-302c [238]. This 
study utilized a protein lysate microarray approach where a library of pre-miRs were 
transfected into MCF-7 and T47D cell lines, and the expression of ERa was analyzed 
in the protein lysates. 
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MICRORNA AND ENDOCRINE RESISTANCE 
Computational analysis of microRNAs have identified miRNAs and their 
targets that have a role in fulvestrant resistance [239]. miR-2211222 has been reported 
to promote TAM-resistance by targeting ERa and the cell cycle regulator p27 (also 
known as Kipl) [233,240,241]. Miller et al. showed that miR-221/222 is 
overexpressed in ERa-negative cells lines and tumors, as well as HER2-positive 
tumors. Overexpression of miR-2211222 was associated with fulvestrant-resistance 
[235]. Prolonged fulvestrant treatment induced miR-2211222 expression in MCF-7 
cells. Some of the signaling pathways that are involved in promoting the miR-
2211222-mediated fulvestrant resistance and oncogenic activity include the ~-catenin, 
TGF-~ and p53 pathways [235]. miR-2211222 is also increased in 
CD44+CD24-IIOWlineage- human breast cancer stem cells, indicating a role for these 
stem cells in drug resistance [242]. A study by Lu et al. shows that anti-miR-221 
suppressed the growth of TAM-resistant xenografts in mice [243]. miR-15a/16 was 
found to downregulate the anti-apoptotic gene BCL2 and promote TAM resistance in 
MCF-7 cells expressing the HER2delta16 mutant [244]. miR-451, a tumor suppressor 
miRNA was reported to be suppressed in MCF-7 derived cell lines that are T AM-
resistant [245]. miR-451 targets the expression of 14-3-3~, an anti-apoptotic gene that 
is overexpressed in TAM-resistant tumors and is also associated with poor clinical 
outcome in breast cancer. Thus the loss of miR-451 in ER-positive breast cancer 
upregulates 14-3-3~ and contributes to TAM-resistance. 
A PubMed search for 'MicroRNA and endocrine resistance III breast cancer' 
generates 12 publications as of September 2012. Most recently, global miRNA 
expression profiling using Exiqon microarrays in 152 ERa + tumors in 52 patients 
who received adjuvant tamoxifen as mono-therapy identified 10 miRNAs that 
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discriminated between patient samples according to patient outcome[246] . Patients 
with recurrence in general had lower levels of miRs- 190b, 339-5p, 520c-3p, 520g, 
520h, 139-3p, 204, 502-5p, 365, and 363. However, none of the data were 
statistically significant except that miR-7 increased with tumor grade. The authors 
concluded that "the miRNA profile does not seem to provide information with regard 
to the probability of recurrence following adjuvant tamoxifen-treatment in post-
menopausal ER+ breast cancer patients." [246]. However, they also noted that tumor 
heterogeneity might be a factor in miRNA expression. 
DISSERTATION SPECIFIC AIMS AND HYPOTHESES 
As reviewed in Chapter I, breast cancer is one of the leading causes of death 
among women in the United States [1]. Although TAM prevents recurrence of breast 
cancer in women, about 40% of women who receive adjuvant hormonal therapy 
acquire resistance [53,248]. The mechanisms of acquired endocrine resistance remain 
to be fully elucidated [249]. This study was focused towards identifying miRNAs that 
are dysregulated in acquired endocrineffAM- resistant breast cancer. By identifying 
miRNAs that are differentially expressed in antiestrogen-sensitive MCF-7 cells versus 
antiestrogen-resistant L Y2 breast cancer cells, it would be possible to use them as 
prognostic markers of antiestrogen resistance in breast cancer. 
Our laboratory identified miRNAs that are differentially regulated by TAM in 
endocrine-sensitive MCF-7 and endocrine-resistant L Y2 human breast cancer cells 
[161,247]. Microarray expression profiling identified miRNAs that are regulated by 
E2 and TAM. They were found to be regulated in the opposite direction in MCF-7 
and L Y2 cells. Q-PCR was preformed to confirm the expression 12 miRNAs that 
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showed significant opposite expression between the two cell lines. Bioinformatic 
prediction identified 36 putative mRNA targets of the 12 miRNAs whose expression 
was validated by Q-PCR. Some of the mRNA targets include PDCD4, BCL2, 
CYPIBl, ERBB3. ZEBl, a target of miR-200 family of miRNAs and a promoter of 
EMT, was found to be overexpressed in L Y2 cells when compared to MCF-7 cells. 
This was a significant finding as it indicated that L Y2 cells represent cells that have 
undergone EMT. This study identified miR-200 family of miRNAs to have a role in 
suppressing endocrine-resistance in breast cancer. 
Identification of specific miRNAs and their gene targets will advance our 
understanding of mechanisms of antiestrogenlendocrine-resistant breast cancer. The 
overall hypothesis of this proposal is that miRNAs are dysregulated in acquired 
endocrine-resistant breast cancer. 
The specific aims to test the hypothesis were: 
SPECIFIC AIM 1: Identify miRNAs oppositely regulated by 4-0HT in 
antiestrogen-sensitive MCF -7 and antiestrogen-resistant L Y2 human breast 
cancer cells. 
I hypothesized that there is inverse regulation of miRNAs in tamoxifen-sensitive 
versus-resistant breast cancer cell lines, and that the regulation of these miRNAs that 
are altered in tamoxifen resistance is mediated through the ER. Microarray was used 
to identify miRNAs that are differentially expressed between MCF-7 and L Y2 cells. 
Results of the microarray analyses were validated by quantitative real time 
polymerase chain reaction (Q-PCR). 
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SPECIFIC AIM 2: Identify the genes targeted by select miRNAs and correlate 
these miRNAs with changes in mRNA in MCF-7 and LY2 cells. 
I hypothesized that changes in miRNA expression correlate with changes in target 
gene expression in MCF-7 and L Y2 cells. miRNAs thus mediate dysregulated 
expression of target oncogenes or tumor suppressors and hence alter critical gene 
pathways in tamoxifenlendocrine-resistance. Bioinformatics was used to identify 
putative targets of select miRNAs that were identified and some were experimentally 
verified in Aim 1. 
SPECIFIC AIM 3: Determine if knockdown of miRNAs upregulated and 
overexpression of miRNAs downregulated in endocrine-resistant breast cancer 
cells restore endocrine-sensitivity. 
I hypothesized that changes in miRNA and mRNA expression correspond to changes 
in functional outcomes in cells. These changes can be reversed by knockdown or 
overexpression of those miRNAs that are up or downregulated respectively. 
Transfection using anti-miRNA or precursor miRNA oligonucleotides followed by 
functional assays were used to determine whether knockdown or overexpression of 
miR-200 restored endocrine-sensitivity/resistance and alter biological functions in 
cells. 
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CHAPTER III: DIFFERENTIAL EXPRESSION OF MICRORNAs IN 
TAMOXIFEN- SENSITIVE MCF-7 VERSUS TAMOXIFEN-RESISTANT LY2 
BREAST CANCER CELLS 
The text of this chapter was published in Cancer Lett. 2011 Dec 26;313( 1 ):26-43 
1. INTRODUCTION 
The ability of selective estrogen receptor modulators (SERMs, e.g., tamoxifen 
and raloxifene) and aromatase inhibitors (AI) to prevent disease recurrence in 
patients whose initial breast tumors expressed estrogen receptor alpha (ERa) provides 
compelling data supporting the role of ERa in the pathogenesis of breast cancer [250]. 
Unfortunately, approximately 40% of patients relapse after tamoxifen (TAM) or other 
endocrine therapies [251]. The mechanisms for the acquired resistance to endocrine 
therapies is complex and, even in the presence of continued ERa expression, includes 
amplification of growth factor signaling pathways, e.g., epidermal growth factor 
receptor (EGFR), MAPK, PI3K1AKT, JNK, and p38 MAPK [251-253], but the role 
of microRNAs in endocrine-resistance remains to be fully elucidated. 
MicroRNAs are short, non-coding RNAs that regulate gene expression at the 
post-transcriptional level by direct binding to the 3'UTR of mRNA targets within the 
ribonucleoprotein RNA-induced silencing (RISC) complex, causing translational 
repression usually accompanied by mRNA decay [254,255]. miRNAs regulate 
diverse cellular processes including differentiation, replication, migration, and 
apoptosis [256]. Microarray technology has been used to generate miRNA profiles 
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and demonstrate aberrant miRNA expression in a variety of cancers including breast 
tumors and cell lines [257-262]. These miRNA expression profiles correlate with 
classification of tumor grade and patient prognosis [257,258,263]. Altered miRNA 
expression in cancer may result from chromosomal rearrangements, deletions or 
epigenetic modifications in DNA or chromatin structure [263]. Bioinformatic 
analyses are used to identify putative mRNA targets of miRNAs, thus linking 
miRNAs to the regulation of complex protein networks involved in a variety of 
cellular functions [264]. miRNAs in breast cancer cells function as tumor 
suppressors, e.g., Let-7 family members, miR-125a and miR-125b, and miR-200; or 
as oncogenes, i.e., 'oncomirs', e.g., miR-21, miR-lOb, miR-155, and the miR-17-92 
cluster [262,265]. 
miRNAs are processed from longer transcripts called precursor (pre)-miRNAs 
by Dicer within the cytoplasm. Pre-miRNAs are, in tum, the products of the 
processing, within the nucleus by DROSHA, of the initial miRNA gene transcripts 
called primary (pri)-miRNAs [266]. Recent studies have identified miRNAs 
regulated by estradiol (E2) in breast cancer cells and other cells and tissues (reviewed 
in [267]). For example, we and others reported that miR-21 and the Let-7 family of 
miRNAs are downregulated by E2 in breast cancer cells [260,261,267,268]. 
Interestingly, E2 upregulates transcription of miR-17 -92 and its paralog miR-106a-363 
clusters in MCF-7 human breast cancer cells, but appears to delay processing of the 
miR-17-92 gene product into its final miRNAs, including miR-18a and miR-20a 
[269], although the mechanism remains to be identified. 
There are only a few studies of miRNA in TAM/endocrine-resistant breast 
cancer cells. Cell-based studies found that miRNA-2211222 are overexpressed in 
TAM-, fulvestrant-, and tumor necrosis factor (TNF)- resistant derivative of MCF-7 
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cells [270-272]. However, no one has examined the effect of TAM on the expression 
of miRNAs in TAM-sensitive versus resistant breast cancer cells. 
To investigate whether antiestrogen-resistance correlates with changes in 
miRNA expression, we profiled miRNA expression in TAM- sensitive MCF-7 and 
TAM/endocrine-resistant LY2 human breast cancer cells. LY2 cells were derived 
from MCF-7 by serial passage in the anti estrogen LY 117018, a precursor to 
Raloxifene (RAL) [273], and express wild-type ERa. rnRNA levels similar to MCF-7 
cells [274], but are resistant to TAM, RAL, and fulvestrant (lCI 182,780) [275]. I 
hypothesized that differences in miRNA expression with TAM treatment between the 
TAM-sensitive MCF-7 versus TAM-resistant L Y2 cells would identify miRNAs and 
their rnRNA gene targets contributing to antiestrogen-sensitivity and resistance, 
respectively. miRNA microarrays were used to identify TAM-regulated rniRNAs in 
these two cell lines. This study identified 97 miRNAs that were differentially 
expressed between the two cell lines and focused on 12 rniRNAs that showed the 
greatest difference in expression between the two cell lines. Quantitative real time 
polymerase chain reaction (Q-PCR) was used to confirm the results obtained by 
microarray. In addition to miRNAs differentially regulated in the two cell lines, eight 
endogenous controls, including 6 miRNAs, 5S rRNA, and SNORD38B, were 
identilied from the microarray data and their expression confirmed by Q-PCR. 
A search of the Sloan-Kettering Targets and Expression 
(http://www.microrna.orglmicrorna/getDownloads.do) dataset was used to identify 36 
putative gene targets of these miRNAs from amongst those that were reported to be 
regulated by 4-0HT in MCF-7 cells [276]. Q-PCR was used to examine the 
expression of 8 miRNAs. Q-PCR and Western analyses were used to examine the 
expression of gene/protein targets of the miRs- 21, 125b, 200a, 200b, 200c, 221 and 
29 
222: PDCD4IPdcd4, BCL2/Bcl-2, CYP1Bl, ERBB3IErbB3, ESR1 IERa, and ZEB-l. 
Results from this chapter show opposite regulation of select miRNAs and target 
proteins between the two cell lines, thus indicating a putative role of these miRNAs in 
TAM/endocrine resistance. 
2. MATERIALS AND METHODS 
2.1 Cells and treatments 
MCF-7 human breast cancer cells were purchased from ATCC (Manassas, 
VA, USA) and maintained in IMEM supplemented with 10% fetal bovine serum 
(PBS) and 1 % penicillinlstreptomycin (Invitrogen, Carlsbad, CA, USA). L Y2 
tamoxifenlfulvestrant-resistant human breast cancer cells were provided by Dr. Robert 
Clarke, Georgetown University, and were used at P<16 from this source. LY2 cells 
were originally derived from MCF-7 cells by selection in increasing concentrations of 
L Y 117018 [273]. L Y2, selected for resistance to L Y 117018, are cross-resistant to 
TAM, raloxifene, fulvestrant (ICI 182,780), and are ERa positive, although ERa 
protein expression is lower than MCF-7 cells [273,277]. LCC 1, LCC2, LCC9 are 
also derivatives of MCF-7 cell lines that are E2, tamoxifen, and multiple SERM-
independent, respectively [278], and were provided by Dr. Robert Clarke, 
Georgetown University, and were, like LY2, used at P<16 from this source. MDA-
MB-231 'triple negative' breast cancer cells were purchased from ATCC. E2 and 4-
OHT were purchased from Sigma (St. Louis, MO, USA). ICI 182,780 was from 
Tocris (Ellisville, MO, USA). Prior to treatment, the medium was replaced with 
phenol red-free IMEM supplemented with 5% dextran charcoal-stripped PBS (DCC-
PBS) and 1 % penicillinlstreptomycin (stripped medium) for 48 h (referred to as 
'serum-starving' or 'serum starved' cells). Cells were treated with ethanol (EtOH, the 
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vehicle control, 0.01 % final volume), 10 nM E2 or 100 nM 4-0HT for 6 h. For the 
microarray profiling, 4 separate experiments (biological replicates) were performed at 
different times over a 6 month period for each cell line. Note: Referrals in the text to 
ER and not specifically to ERa or ER~ indicated that either ERa or ER~ or both may 
be involved in the response tested. 
2.2 MicroRNA microarray analyses 
RNA was isolated from MCF-7 and L Y2 cells, treated as above, using the 
mirVana miRNA Isolation Kit from Ambion (Austin, TX, USA) and sent to Exiqon 
(http://exiqon.comJ/) where the RNA samples were labeled with either Hy3 or Hy5 
fluorescent labels and hybridized into the miRCURY LNATM microarray (miRbase 
11.0 human array). This micro array featured 1275 bone fide and putative human 
miRNAs plus additional controls. Four separate experiments (biological replicates) 
were performed. Data analysis was performed by Exiqon as follows: clustering of 
miRNAs was performed using log2 (Hy3/Hy5) ratios which passed the filtering 
criteria on variation across sample groups using a two tailed T-test p-value < 0.001. 
The Hy3 signals were normalized using the single color approach 'Quantile' followed 
by a background correction. The data were deposited in GEO as GSE28267 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE28267 . The subset of 
miRNAs showing the highest variation among the 1275 miRNAs were used for 
clustering which provided a subset of 50 miRNAs that showed maximum variation 
between the two cell lines. The heat map (Figure 1) shows the result of clustering of 
miRNAs. The miRNA clustering tree is shown on the left and top. Each column 
represents a treatment and each row a miRNA. 
2.3 RNA isolation and quantitative Real-Time-PeR (Q-PCR) for miRNA 
expression 
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miRNA-enriched total RNA was extracted from MCF-7 and LY2 cells treated 
as above using the miRNA isolation kit (Exiqon). The quality and quantity of the 
isolated RNA was analyzed using a NanoDrop spectrophotometer and Agilent 
Bioanalyzer. cDNA was synthesized using the miRCURY LNA ™ first strand cDNA 
synthesis kit (Exiqon) and Q-PCR was performed using the miRCURY LNA ™ 
SYBR Green master mix (Exiqon) using the miRNA primer sets for miR-I0a, -21, -
22, -12Sb, -181 a, -200a, -221 and -222 (Exiqon). SNORD38B and SSRNA were used 
for normalization of miRNA expression. Analysis and fold change was determined 
using the comparative threshold cycle (Ct) method. The change in miRNA 
expression was calculated as fold-change, i.e., relative to EtOH-treated (control). 
2.4 RNA Isolation, RT -PCR and Q-PCR for mRNA expression 
RNA was extracted from cells using Trizol (Invitrogen) or RNeasy (Qiagen). 
The High Capacity cDNA Reverse Transcription kit (PE Applied Biosystems) was 
used to reverse transcribe total RNA using random hexamers. Q-PCR for BCL2, 
CYP1Bl, ERBB3, ESR1, PDCD4, and 18S using Taqman primers and probes as 
Assays-on-Demand was performed in the ABI PRISM 7900 SDS 2.1 (PE Applied 
Biosystems) using relative quantification. Analysis and fold differences were 
determined using the comparative CT method. Fold change was calculated from the 
MCT values with the formula 2-MCT and data are relative to EtOH-treated cells. 
2.S Whole cell and nuclear lysate preparation for western blotting 
Whole cell lysates were prepared and western blots were performed as 
described [277]. Nuclear extracts (NE) were prepared using the NE-PER kit from 
Thermo Scientific (Rockford, IL, USA). Antibodies were purchased as follows: ERa 
(Santa Cruz Biotechnology, Santa Cruz, CA, USA), ER~ (HI SO, Santa Cruz, CA, 
USA), Argonaute 2 (Anti-Ago2, clone 9E8.2, #04-642, Millipore, Billerica, MA, 
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USA), Pdcd4 (GeneTex,Irvine, CA ), Bcl-2 (Assay Designs, Plymouth Meeting, PA), 
E-cadherin (Cell Signaling, Danvers, MA, USA), a-tubulin (Thermo Scientific, 
Rockford, IL, USA), ~-actin (Sigma, St. Louis, MO, USA). The ZEB-l antibody was 
generously provided by Dr. Douglas Darling, University of Louisville. 
Chemiluminescent bands on the PVDF membranes were visualized on a Kodak 
Carestream Imager using Carestream Molecular Imaging software (New Haven, CT, 
USA). 
2.6 Statistical analysis 
Data preprocessing was performed on two sets of samples sent to Exiqon at 
different times (sample set 1 and 2 contained 6 and 14 cell treatments, respectively; 
different miRNA chips were utilized for the 2 sets of samples) separately before 
combining them for further analysis. Two-step filtering (1) excluding empty and 
blank spots and (2) keeping only those spots for which foreground intensities were 
greater than 1.1 x background intensities for 2 or more samples in the 6-sample group 
and 10 or more samples in the 14-sample group was done before normalization. For 
the remaining spots, background intensities were subtracted from the foreground 
intensities. Since even after the filtering step, some spots had backgrounds larger than 
foregrounds; we treated those as missing and imputed them using the k-nearest 
neighbor algorithm. Normalization within-arrays was performed using the loess 
method [279], while for between-arrays the quantile method was applied. The two 
sets of samples were then matched by their miRNA names and combined for further 
analysis. 
In order to identify miRNAs which are expressed by MCF-7 and L Y2 cells 
treated with EtOH and 4-0HT and by MCF-7 cells treated with E2, the four technical 
replicates on each chip and the four arrays (biological replicates) corresponding to 
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each of the five treatment groups (n=20) were averaged. All expression values were 
represented as log2 ratios of Hy3 (experimental) versus Hy5 (universal reference). 
Differential expression of miRNAs between different TAM-sensitive and TAM-
resistant cell lines treated with either 4-0HT or EtOH were determined by fitting a 
hierarchical linear model using the limma package [280] and testing the 
corresponding contrasts of interest, e.g., MCF-7 vs. L Y2 treated with 4-0HT, MCF-7 
vs. L Y2 treated with EtOH, and E2 vs. 4-0HT treated MCF-7 cells, for each miRNA. 
Fold change, adjusted t-statistic, unadjusted and false discovery rate (FDR) adjusted 
p-values were calculated for each miRNA for each comparison. Of the 225 miRNAs 
that passed the filter for analysis, only those miRNAs with adjusted p-values below 
0.10, i.e., FDR of 10%, were considered as differentially expressed. 
2.7 Gene pathway analysis 
Functional and network analyses of differentially expressed miRNAs gene 
expression changes were performed using Ingenuity Pathways Analysis (lPA) 8.8 
(Ingenuity® Systems, http://www.ingenuity.com). Networks were generated using 12 
differentially expressed miRNAs (Figure 3) that were uploaded into IP A. Analysis 
considered all genes from the dataset that met the 2-fold (p-value < 0.05) change cut-
off and that were associated with biological functions in the Ingenuity Pathways 
Knowledge Base. For all IPA analyses, Fisher's exact test was used to determine the 
probability that each biological function assigned to the genes within the data set was 
due to chance alone. 
34 
3. RESULTS AND DISCUSSION 
Identification of miRNAs differentially expressed in MCF-7 and LY2 cells. 
To identify miRNAs that might be involved in T AM- resistance, we compared 
the miRNA transcription profiles between MCF-7 TAM-sensitive and LY2 TAM-
resistant cells in response to 4-0HT using ethanol as the vehicle control. The cells 
were treated for 6 h, a time point selected as that at which maximal primary ERa-gene 
target transcription occurs [281]. Since serum levels of 4-0HT in breast cancer 
patients on oral TAM-citrate are 8-18 nM and breast tumors concentrate 4-0HT to 74 
nM - 1.5 IlM [282], the 100 nM 4-0HT concentration used in our experiments is at 
the lower range of that found in women on TAM therapy. In addition, MCF-7 cells 
were treated with 10 nM E2, as per previous investigations of miRNA transcriptional 
responses [260,261,268,269,283]. Four separate experiments were performed for 
each treatment group and cell line. 
A total of 97 miRNAs exhibited differential expression between TAM-
sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-0HT treatment 
(Figure 1, Tables 1 and 2). Forty-seven miRNAs were exclusively differentially 
expressed between the two cell lines in the presence of EtOH and 21 miRNAs were 
exclusively differentially expressed between the two cell lines in the presence of 4-
OHT. Twenty-nine miRNAs were commonly differentially expressed between the 
two cell lines both with treatment by EtOH or 4-0HT. A Venn diagram is provided 
to schematically represent these results (Figure 2, left hand side). We represent the 
same data by separating up-regulated and down-regulated miRNAs on the right hand 
side of Figure 2. For example, 53 miRNAs demonstrated enhanced and 23 miRNAs 
demonstrated reduced expression in MCF-7 cells when compared to L Y2 cells treated 
with the vehicle control EtOH (Table 1). Twenty-nine miRNAs demonstrated 
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increased and 21 miRNAs demonstrated decreased expression in MCF-7 cells when 
compared to L Y2 cells treated with 4-0HT (Table 2). Differentially expressed 
miRNAs for EtOH-treated MCF-7 versus LY2 are shown in Table 1, 4-0HT-treated 
MCF-7 versus LY2 are shown in Table 2, and E2 versus 4-0HT-treated MCF-7 are 
shown in Table 3. Of the total 225 miRNAs analyzed, 128 miRNAs were not 
differentially expressed between MCF-7 and L Y2 in cells treated with EtOH or 4-
OHT (data not shown). One miRNA, miR-423-5p demonstrated higher and miR-
181a, demonstrated lower expression in MCF-7 cells treated with E2 compared to 
MCF-7 cells treated with 4-0HT (Table 3). 
From that list of 76 miRNAs showing opposite direction of expression in 
MCF-7 versus L Y2 cells (Figure 2, Tables 1 and 2), 12 miRNAs were selected for 
further study (Figure 3A and B). The microarray expression data show that miR-lOa, 
miR-22, miR-29a, miR-125b, miR-181a, and miR-222 were lower in EtOH-treated 
MCF-7 than in LY2 cells. In contrast, miR-21, miR-93, and miR-200a, b, and c were 
lower in EtOH-treated LY2 than MCF-7. Of these miRNAs, only miR-21 and miR-
18la were E2 regulated, i.e., inhibited by E2, in MCF-7 cells. Of these miRNAs 
exhibiting opposite expression in MCF-7 and L Y2 cells, miR-lOa, miR-2l, miR-22, 
miR-125b, miR-18Ia, miR-200a and miR-222 were selected for Q-PCR validation. 
In addition, we included miR-221 for analysis because of its reported role in 
TAM/endocrine resistance [270], although its expression was not significantly 
different between MCF-7 and L Y2 cells in the microarray. A literature review of the 
relationship between these miRNAs and breast cancer is summarized in Appendix 1. 
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Figure 1: Heat map (hierarchical clusters) of significant differences in miRNA 
expression between MCF -7 and L Y2 cells. 
MCF-7 and L Y2 cells were treated with EtOH, or 100 nM 4-0HT for 6 h and miRNA 
expression determined by microarray analyses of 4 separate experiments. The 
heatmap shows 97 miRNAs significantly differentially expressed (adjusted p-value < 
0.10) for at least one of the two comparisons between cell lines (MCF-7IEtOH versus 
LY2IEtOH and MCF-7/4-0HT vs. LY2/4-0HT, see Tables 1 and 2, respectively). 
Each row of the heat map represents a gene, and each column represents a cell 
line/treatment group (as labeled at the bottom. Yellow indicates an increase in 
miRNA gene expression (relative to the other expression measurements in the same 
row) and orange/red indicates a decrease in expression. 
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Table 1: MicroRNAs Differentially Expressed in MCF-7IEtOH VS. LY2IEtOH in 
human breast cancer cells. 
Gene expression from TAM-sensitive (MCF-7) and TAM-resistant (LY2) human 
breast cancer cells treated with EtOH were filtered and the average fold change for 
each gene was calculated for MCF-7 VS. L Y2. Only those genes that demonstrated a 
statistically significant (adjusted p < 0.10) increase or decrease in expression for the 
MCF-7IEtOH VS. LY2IEtOH expression comparison are included in this table. Note 
that MCF-7IEtOH VS. LY2IEtOH means that expression for LY2 cells was utilized as 
reference group. Therefore, ratios above 1.0 indicate higher expression in MCF-7 
than L Y2 whereas ratios below 1.0 indicate lower expression in MCF-7 vs. L Y2 cells 
1 empirical Bayes' t-statistic from the hierarchical linear model fitted by limma, see 
Materials and Methods for description 
2 p_ Value corrected for the false-discovery rate (FOR) 
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Table 2: MicroRNAs Differentially Expressed in MCF-7/4-0HT VS. LY2/4-0HT in 
human breast cancer cells 
Gene expression values from TAM-sensitive (MCF-7) and TAM-resistant (LY2) 
human breast cancer cells treated with 100 nM 4-0HT for 6 h were filtered and the 
average fold change for each gene was calculated for MCF-7 vs. L Y2. Only those 
genes that demonstrated a statistically significant (adjusted p < 0.10) increase or 
decrease in expression for the MCF-7/4-0HT VS. L Y2/4-0HT expression comparison, 
were included in this table. Note that MCF-7/4-0HT VS. LY2/4-0HT means that 
expression for L Y2 cells was utilized as reference group. Therefore, ratios above 1.0 
indicate higher expression in MCF-7 relative to L Y2 and conversely, ratios below 1.0 
indicate lower expression in MCF-7 compared to L Y2 cells. 
I empirical Bayes t-statistic from the hierarchical linear model fitted by limma, see 
Materials and Methods for description 
2 p_ Value corrected for the false-discovery rate (FOR) 
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Table 3: MicroRNAs Differentially Expressed in MCF-71E2 VS. MCF-7/4-0HT in 
human breast cancer cells. 
Gene expression from TAM-sensitive (MCF-7) and TAM-resistant (LY2) human 
breast cancer cells were filtered and the average fold change for each gene was 
calculated for MCF-7 treated with E2 vs. MCF-7 treated with 4-0HT. Only those 
genes that demonstrated a statistically significant (adjusted p < 0.10) increase or 
decrease in expression for the MCF-71E2 vs. MCF-7/4-0HT expression comparison 
were included in this table. Note that MCF-71E2 vs. MCF-7/4-0HT means that 
expression for MCF-7 cells treated with 4-0HT was utilized as reference group. 
Therefore, ratios above 1.0 indicate an increase E2 relative to 4-0HT-treated MCF-7 
cells and ratios below 1.0 indicate a decrease in expression in 4-0HT-treated cells 
relative to E2-treated MCF-7 cells. 
1 empirical Bayes t-statistic from the hierarchical linear model fitted by limma, see 
Materials and Methods for description 
2 p-Value corrected for the false-discovery rate (FDR) 
MCF-lif, H'f5J1.l MCF-]l4·01ff fold dlanJ!' I-St.U p-Val.., Mjusted p-val""" 
G<nrIOs miRNA&<,M hmily 
17%S hu-miR-I:lJ.Sp 1.6.l 429 Qcw ru.'S2 
1I0H Mia-mill-ISla" OJ] -4.H (lCW M41l 
42865 hu-miR-181. 0.21 154 O(XlI 011.)4 
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Figure 2: Venn diagrams summarizing differentially expressed (DE) miRNAs. 
A) Venn diagram of miRNAs differentially expressed between TAM-sensitive (MCF-
7) and TAM-resistant (LY2) human breast cancer cells by the indicated treatments 
(EtOH and 4-0HT). Cells were treated as described in Figure 1. B) Venn diagram 
showing miRNAs either UP- (increased expression) or DOWN- (reduced expression) 
regulated between TAM-sensitive (MCF-7) and TAM-resistant (LY2) human breast 
cancer cells by treatment. 
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Figure 3: Select miRNAs that are differentially expressed in MCF-7 (TAM-S) 
and LY2 (TAM-R) breast cancer cells. 
These 12 miRNAs were identified as differentially expressed in microarray analysis 
of miRNAs in EtOH, E2 or 4-0HT treated cells. Values are log2(Hy3/Hy5) ratios in 
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Selection of endogenous control genes for Q-PCR normalization and validation 
of select miRNAs by Q-PCR 
Prior to performing Q-PCR to confirm the miRNA microarray data it was 
necessary to identify endogenous control genes (ECG) for normalization of miRNA 
transcript expression. First, we compared the expression of U6 (RNU6-1) and U48 
(RNU48) RNA genes, traditionally used as controls for miRNA expression [284-286], 
in MCF-7 and LY2 cells after 6 h of 4-0HT or EtOH treatment (Figure 4A and 4B). 
U6 expression was increased by 4-0HT in MCF-7 and reduced by 4-0HT in L Y2 
cells. U48 expression was comparable between the two cell lines and unaffected by 
4-0HT. 
Eight additional candidate ECG were identified as showing low variation in 
expression in the miRNA microarray: high signal: miR-16, Let-7f, and 5SrRNA; 
medium signal: SNORD38D (U38B), Let-7d, and miR-340; low signal: miR-765, 
miR-744, miR-887, miR-92b. Eight of these ECG were screened for their expression 
in MCF-7 and L Y2 cells after 6 h or vehicle (EtOH) or 100 nM 4-0HT treatment 
(Figure 4A and 4B). Two general conclusions can be made from these data: 1) ECG 
expression differs between the two cell lines; 2) 4-0HT affects ECG expression more 
in MCF-7 than L Y2 cells. Expression of Let-7f was reduced by 4-0HT in both cell 
lines. miR-744 was reduced by 4-0HT whereas Let-7d and miR-340 were increased 
by 4-0HT in MCF-7 cells. Overall, the best ECG in MCF-7 and L Y2 cells are U48, 
5S rRNA, U38B, and miR-765 for high, medium, and low expression miRNAs, 
respectively. Because of the low expression of miR-765, we selected 5S rRNA, U48, 
and U38B to normalize miRNA expression in the rest of the studies in this chapter. 
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Figure 4: Selection of endogenous control genes for analysis of miRNA 
expression by Q-PCR 
The expression of RNU6-1 (U6) and RNU48 (U48) RNA genes, traditionally used as 
controls for miRNA expression and eight candidate endogenous control genes (ECG) 
identified by miRNA microarray: high signal: miR-16, Let-7f, and 5SrRNA; medium 
signal: SNORD38D (U38B), Let-7d, and miR-340; low signal: miR-765 and miR-744 
were examined in MCF-7 (A) and LY2 (B) cells treated for 6 h with EtOH (vehicle 
control) or 100 nM 4-0HT. (C) The expression of the Let-7 family members was 
determined by Exiqon Microarray analysis of miRNAs in EtOH, E2 or 4-0HT treated 
cells, as indicated. Values are log2 (Hy3/Hy5) ratios in the sample versus the 
common reference pool. Each value is the avg. ± SEM of 4 separate experiments. D) 
The relative expression of MYC in MCF-7 and LY2 cells treated with EtOH, 10 nM 
E2, or 100 nM 4-0HT for 6 h was determined by Q-PCR and CT values are the mean 
of 3 separate determinations ± SEM. E) Relative MYC expression in MCF-7 was 
normalized to 18S. * P < 0.05 versus EtOH control. F) The relative expression of 
ESRI (ERa) in MCF-7 cells treated as in panel D. CT values are shown as avg. ± 
SEM of 3 replicates in one experiment. The inset shows a western blot of ERa 
protein. The blot was stripped and reprobed for ~-actin. The ratio of ERa/~-actin in 
MCF-7 was set to I and the relative expression of ERa in MCF-7 was 0.4 = 60% 
lower ERa in L Y2 compared to MCF-7 cells. 
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Although Let-7a was reported to be an ECG for miRNA [285], Let-7a expression was 
increased by E2 and reduced by 4-0HT in MCF-7 cells (Figure 4C). Let-7 family 
members are highly conserved in sequence and function across species [287]. 
Misregulation of Let-7 leads to a less differentiated cellular state and the development 
of cancer; hence, Let-7 family members are considered as tumor-suppressor miRNAs 
[288,289]. We observed that 4-0HT repressed the expression of all eight Let-7 
family members in MCF-7 cells and none of the Let-7 family members in LY2, 
commensurate with a less differentiated cellular state. Let-7b, Let-7c, Let-7g, and 
Let-7i showed opposite expression between MCF-7 and L Y2 cells. Since Let-7a 
[290] and Let-7g [291] downregulate Myc and high Myc expression results in a 
negative feedback loop inhibiting Let-7a expression [287], we examined Myc mRNA 
in MCF-7 and L Y2 cells (Figure 4D). Based on the higher Let-7 expression in LY2, 
we expected lower Myc in L Y2 and our data confirmed significantly lower Myc 
expression in L Y2 compared with MCF-7 cells (Figure 4D). In agreement with an 
earlier report [292], E2 increased and 4-0HT inhibited Myc transcription in MCF-7 
cells (Figure 4E). Since transient overexpression of Let-7a, Let-7b, and Let-7i was 
reported to inhibit ERa expression in MCF-7 cells [293], we examined ESRI mRNA 
and protein levels in MCF-7 and L Y2 cells. As expected, ESRI mRNA and ERa 
protein were lower in endocrine-resistant L Y2 compared to endocrine-sensitive MCF-
7 cells (Figure 4F). The reduced expression of ERa in L Y2 also reflects higher 
expression of miR-221 and miR-222 that have been reported to suppress ERa 
expression [234,294,295]. 
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Figure 5: Q-PCR analysis of the miRNA expression in MCF -7 and L Y2 cells. 
A) Cells were treated with EtOH, 10 nM E2, or 100 nM 4-0HT for 6 h. Where 
indicated MCF-7 (B) and LY2 (C) cells were pretreated with 100 nM ICI 182,780 for 
6 h. Values are the average of 3-8 separate experiments were normalized by U38 or 
5S rRNA and are expressed as fold relative to EtOH-treated MCF-7 expression for 
each miRNA. In A: * Significantly different from EtOH in MCF-7. In Band C: * 
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To validate the changes in miRNA expression detected in the miRNA 
microarrays, Q-PCR was performed on 7 of the 12 miRNAs in Figure 3: miR-lOa, 
miR-21, miR-22, miR-125b. miR-181a, miR-200a and miR-222 in MCF-7 and LY2 
cells treated with EtOH or 100 nM 4-0HT for 6 h, and MCF-7 cells treated with 10 
nM E2 for 6 h (Figure 5A). In addition, miR-221 was analyzed because it, along with 
miR-222, has been reported to be overexpressed and involved in endocrine-resistance 
in breast cancer cells [270,283,296]. 
For comparison between the two cells lines, miRNA expression was 
normalized to the value in EtOH treated MCF-7 cells. There was general agreement 
in the direction (up- or down- regulation) of miRNA expression in MCF-7 and L Y2 
cells between the Q-PCR and microarray data. The exception is that 4-0HT increased 
miR-200a in MCF-7 cells in Q-PCR. In agreement with other recent results 
examining E2-regulation of miRNA expression in MCF-7 cells [260,261,268,269], the 
miRNA expression changes in response to E2 or 4-0HT were less than five-fold. E2 
decreased miR-21 expression in MCF-7 cells, as observed in our earlier experiments 
[268] and as reported by others [261]. 4-0HT increased miR-21 expression in MCF-7 
cells. LY2 cells had lower expression of miR-21 and miR-200a, in agreement with 
the data in the microarray (Figure 3). A recent analysis of miRNA expression in 
breast tumors by deep sequencing showed upregulation of miR-21 in ER+ breast 
tumors relative to normal breast tissue and triple negative breast tumors [297]. 
To determine if the effects of E2 and 4-0HT on miRNA expression were ER-
mediated, MCF-7 cells were pretreated with 100 nM ICI 182,780 (ICI, Fulvestrant) 
for 6 h, a time that reduces ERa protein and activity [298]. For each of the eight 
miRNAs, ICI increased expression relative to EtOH in MCF-7 cells (Figure 5B). 
These data suggest that unliganded ER may suppress transcription of these miRNAs 
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or that some component regulating miRNA expression or processing is inhibited by 
unliganded ER. Alternatively, since ICI is an agonist for GPERlGPR30 [13,299], it is 
possible that ICI activates intracellular signaling pathways, e.g., MAPK, that increase 
miRNA expression. For example, MAPK increases miRNA expression by 
phosphorylating TRBP, a component of the Dicer complex that processes pre-miRNA 
into mature miRNA [300]. Testing GPERlGPR30 is beyond the scope of the current 
study. ICI ablated the inhibition of miR-21 by E2 in MCF-7 cells. These data indicate 
that E2-occupied ER suppresses the transcription of miR-21. The combination of ICI 
and 4-0HT did not further increase miRNA expression in MCF-7 cells with the 
exception of miR-lOa, a result seen in both MCF-7 and L Y2. While the mechanism 
involved for the increase in miR-lOa appears to be, at least in part, ER-mediated, 
future studies are needed to address this mechanism in greater detail. There is only 
one report about miR-lOa regulation [301]. That report found that miR-lOa 
expression increased as mouse embryonic stem cells differentiated into smooth 
muscle cells [301]. Others reported that miR-lOa associates with the 5' UTR of 
mRNAs encoding ribosomal proteins, enhances their translation, increases global 
protein synthesis, and thus contribute to oncogenesis [302]. For miR-21, miR-125b, 
and miR-181a, 4-0HT inhibited the stimulation over basal expression detected with 
ICI treatment in MCF-7 cells. 
For L Y2 cells, ICI had no significant effect on basal miRNA expression 
(Figure 5C). These data indicate that, unlike MCF-7 cells, the regulation of miRNA 
expression in L Y2 cells is independent of ER. These data are in agreement with the 
estrogen-independent, endocrine-resistant phenotype of LY2 cells [273,303]. As 
discussed above, ICI and 4-0HT synergistically increased miR-I0a transcription. ICI 
reduced 4-0HT-stimulated miR-125b and miR-222 expression (Figure 5C), a result 
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implicating ER involvement in 4-0HT-regulating the expression of these miRNAs, a 
result commensurate with higher miR-125b in ERalPR-positive than ERaJPR-
negative breast tumors [304]. The apparent synergy of ICI and 4-0HT in upregulating 
miR-IOa transcription may be mediated by GPR30/GPER, for which both ICI and 4-
OHT are agonists [12]. However, others have reported that an ERa, variant called 
ERa,36, and not GPR30, mediates non-genomic ER signaling, including ICI agonist 
activity [305]. ERa,36 arises from a promoter in the first exon of ERa" but lacks both 
the N- and C terminal transcription activation domains, AF-I and AF-2, respectively, 
of full-length wild type ERa,66 [306,307]. Further studies would be required to 
examine ERa,36 expression in L Y2 cells. However, ERa,36 was not detected using an 
antibody that recognizes epi tope s conserved in ERa,66 and ERa,36 [307,308] 
(Appendix 4). 
Time course ofmiRNA expression in MCF-7 cells 
Time-dependent changes in the expression of 8 miRNAs were detected after I, 
4, 6, and 8 h treatment with EtOH, E2, or 4-0HT (Figure 6). E2 repressed the 
expression of miR-22, miR-125b, miR-181a, miR-200a (except at the 6 h time point), 
and miR-221 (except at the 6 h time point) relative to EtOH. 4-0HT increased 
expression of miR-2Ia, miR-22, miR-181a, and miR-200a relative to EtOH at the 6 h 
time point. 4-0HT inhibited miR-221 expression, although the difference was not 
statistically significant at the 6 h time point. To our knowledge, there are only two 
reports examining the effect of E2 on miRNA at various times (0, 1, 3,4, 6, and 12 h) 
of treatment in MCF-7 cells [260,269]. The time-course of miR-21 expression does 
not agree with a previous report showing E2 increased miR-21 over time [260]. This 
difference is likely the result of differences in the MCF-7 cells used since Bhat-
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N akshatri et al. used MCF-7 cells stably transformed with a bicistronic vector control 
[260] whereas we used MCF-7 cells at passages less than 9 from A TCC. 
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Figure 6: Time course analysis of miRNA expression. MCF-7 cells serum starved 
for 72 h and were treated for 1,4, 6 and 8 h with EtOH, 10 nM E2, or 100 nM 4-0HT. 
Values are the avg. ± SEM of 3-6 separate experiments in which each point was run 
in triplicate. Values were normalized by 5S rRNA and are expressed as fold relative 
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Time course of E2 and 4-0HT regulation of ERa, ER~, and Argonaute-2 (Ago2) 
To determine if changes in miRNA expression with time reflect changes in 
ERa, ER~, or Ago 2 expression, MCF-7 cells were treated with EtOH, E2, or 4-0HT 
for I, 4, 6, or 8 h prior to western blot for ERa, ER~, and Ag02 protein expression 
(Figure 7 A). These data show that ERa was increased after 4 h of treatment with 
EtOH and remained increased through the 8 h time course in MCF-7 cells. Consistent 
with previous investigations [309], E2 reduced ERa and 4-0HT stablized ERa in 
MCF-7 cells. ER~ was increased with EtOH, E2, and 4-0HT treatment for 1 h, but at 
4 h, E2 and 4-0HT reudced ER~. At 6 h, only 4-0HT reduced ER~. At 8 h, ER~ was 
increased and this increase was inhibited by E2 and 4-0HT. Ag02 was unaffected by 
EtOH until 8 h when there was an increase in Ag02. Ag02 was decreased by E2 and 
4-0HT with time and the increase in Ag02 with EtOH at 8 h was further increased by 
4-0HT. This is the first examination of the effect of E2 or 4-0HT on Ag02 
expression. The changes in miR-21 expression with time and treatment correspond to 
the expression of ERa protein and at some time points/treatments appear to inversely 
correspond to ER~ protein expression (Figure 7B). These data suggest that E2-ERa 
regulates miR-21 expression. 
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Figure 7: Time-dependent changes in ERa, ER~, and Ago2 expression in E2- or 
4-0HT- treated MCF-7 cells. MCF-7 cells were serum-starved for 48 h and either 
untreated (No Tx) or treated for 1,4, or 6 h with EtOH, 10 nM E2, or 100 nM 4-0HT. 
A) WCE (30 J..lg protein) were separated on SDS-PAGE gels and western blotted with 
two different ERa antibodies (D-12 and AER320), ER~ antibody H150, or an 
antibody for Ag02. The blot was stripped and re-probed for a-tubulin as a loading 
control. The values below each blot are the ratio of the indicated protein/a-tubulin 
normalized to the No Tx control. The last lane shows MCF-7 cells that were not 
serum-starved or treated. B) The relative expression of miR-21 in MCF-7 cells 
treated as indicated are plotted with ERa (AER320) and ER~ protein expression. The 
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Computational identification of miRNA target mRNA genes in 4-0HT-treated 
MCF-7 cells 
mRNA targets of the 12 miRNAs that were differentially expressed between 
MCF-7 and L Y2 cells (Figure 2) were identified in silica using target identification 
software:, Target Scan 5.1 (http://www.targetscan.org/), Pic Tar (http://pictar.mdc-
berlin.de/), miRanda (http://www.microma.org/microma/getGeneForm.do). and miR 
Base Release 15 (http://www.mirbase.org/).This data was integrated with mRNA 
targets regulated by 4-0HT after 4, 8, 24 and 48 h treatment of MCF-7 cells [276]. 
The gene symbols were transcribed from [276] and were searched against the 
miRanda predicted Human Target Site Predictions data contained in the file named 
human_predictions3ug2008. txt, downloaded from 
http://www.microma.org/microma/home.do. It was necessary to update several of the 
HUGO gene symbols presented in [276] in order to be consistent with the current 
HUGO identifiers for these transcripts in the human predictions dataset. Examples 
include updating Clorf24 to FAM129A, and RENTl to UPFI. All genes listed in 
[276] were found the predicted target of at least one miRNA in the 
human_predictions3ug2008.txt dataset with the exception of SNCG, SLC16A5, 
RAP 1 40, LOC44 1 453, ELF3, LSS, CLIC3, EHD4,SERPINA1, EGFL5, SRD5Al, 
and KRTl3. This analysis identified 36 genes that were regulated by 4-0HT in MCF-
7 cells and which are putative targets of the 12 miRNAs identified in miRNA 
microarray analyses (Figure 8, Appendix 2). Appendix 2 also lists the putative 
miRNA target mRNA genes, their mRNA expression in 4-0HT treated cells at 8 and 
48 h from [310], and whether these data agree with the data on miRNA expression in 
response to 4-0HT (Figure 5). In general, the predicated gene targets agree with the 
direction of miRNA expression in 4-0HT treated MCF-7 cells. 
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In order to identify gene networks involving 12 miRNAs that were differentially 
expressed in L Y2 and MCF-7 cells (Figure 3), Ingenuity Pathway Analysis (IPA) was 
performed. Networks created by IPA are groups of proteins that interact directly or 
indirectly with genes or proteins in a dataset. As expected, IPA identified cancer as 
the top category followed by reproductive system disease and cellular development as 
significantly associated with the miRNAs in the data set (Appendix 6). Core analysis 
using IPA generated 2 networks containing the 12 differentially expressed miRNAs 
and key proteins involved in breast cancer (Appendix 7). Network 1 and 2 shows 35 
and 9 molecules respectively (Appendix 7). The identity and cellular location of these 
molecules are provided in Appendix 3. Functional analysis with IPA tools identified 
14 molecules in network 1 and 5 in network 2 as having roles in breast cancer 
(indicated by red lines in Appendix 7). Network 1 identified Myc as a central node, 
although none of the miRNAs directly connect to Myc. miR-IOa mapped to a number 
of gene targets in Network 1 while miR-200b mapped to only one target, VIM. 
However, recent studies show that downregulation of the miR-200bc/429 cluster is 
associated with breast tumor progression through upregulation of phospholipase C 
gamma 1 (PLCG I) which, in tum, regulates cell mobility, proliferation, and viability 
[311]. APC, MYC, CYRB, CASP3, CSF1, UNCX, NPTX1, miR-lOa, miR-22, miR-
29a, miR-93, miR-200a, miR-205 and miR-222 are the genes associated with breast 
cancer in this network. Network 2 centers on estrogen receptor in breast cancer and 
supports our observation that the expression of miR-21 in MCF-7 cells is regulated by 
ER (Figure 4B). 
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Figure 8: Computational identification of mRNA gene targets of 12 miRNAs 
oppositely expressed in MCF -7 and L Y2 cells. Target prediction software was used 
to identify mRNA targets of the miRNAs. Predicted genes were overlapped with 
microarray data of 4-0HT regulated genes by [310]. This identified 36 gene targets 
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PDCD4, BCL2, CYPIBl, and ERBB3 are differentially expressed in MCF-7 and 
LY2 cells 
Among the 36 putative gene targets in Appendix 2, we focused first on the 
PDCD4 tumor suppressor because we had previously identified PDCD4 tumor 
suppressor as a bone fide mRNA target downregulated by miR-2l in MCF-7 cells 
[268]. Since miR-2l expression was significantly lower in L Y2 than MCF-7 cells, we 
anticipated that PDCD4 mRNA and protein expression would be higher in LY2 than 
in MCF-7 cells. However, PDCD4 mRNA was undetectable in EtOH-treated L Y2 
cells. With 4-0HT treatment, PDCD4 mRNA was detected at low levels in L Y2 cells 
(Figure 9A). Neither E2 nor 4-0HT affected GADPH expression and GADPH CT 
values were similar in MCF-7 and L Y2 cells, indicating that the quality of the RNA 
was not an issue in the lack of PDCD4 expression in control (EtOH)-treated L Y2 cells 
(Appendix 5). 4-0HT reduced PDCD4 mRNA in MCF-7 cells (Figure 8A and 8B), 
consistent with the increase in miR-2l induced by 4-0HT. As reported previously, E2 
increased PDCD4 mRNA (Figure 9A and 9B). We did not detect Pdcd4 protein 
expression in L Y2, although Pdcd4 was expressed in MCF-7 (Figure 8C). 
The anti-apoptotic, pro-survival BCL2 is also a target of miR-21 [268]. Again, 
since miR-2l expression was lower in L Y2, we expected higher BCL2 expression in 
L Y2 than MCF-7 cells. However, BCL2 mRNA could not be detected in L Y2 cells, 
whether EtOH or 4-0HT treated (data not shown). As expected based on our 
previous data and the work of others [268,312], E2 increased BCL2 mRNA in MCF-7 
cells. 4-0HT had no significant effect on BCL2 mRNA expression in MCF-7 cells. 
We did not detect Bcl-2 protein expression in LY2, although Bcl-2 was expressed in 
MCF-7 cells (Figure 9C). Others reported that 1 /lM 4-0HT suppressed Bcl-2 
expression in MCF-7 cells after 7 d of treatment [313]. 
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CfP 1 B 1 is a cytochrome P450 enzyme implicated in the metabolism of 
exogenous and endogenous substrates, including E2, and CfP 1 BI polymorphisms are 
associated with breast cancer risk [314]. CfPIBI was stimulated by 8 h treatment 
with 1 J.lM 4-0HT in MCF-7 cells [310] and is a putative target of regulation by miR-
200 family members that are reduced in L Y2 compared to MCF-7 cells. Because 4-
OHT increased miR-200a expression, we examined CfPIBI expression after 6 h 
treatment with 4-0HT or EtOH in MCF-7 and LY2 cells. CfPIBI mRNA expression 
was very low (CT - 39) in L Y2 cells and 4-0HT did not affect CfP 1 B 1 expression 
(Figure lOA). These results are in contrast to a previous report showing 2-6-fold 
higher CfPIBI in TAM- and fulvestrant- resistant cell lines derived from of MCF-7 
cells [315]. The reason for this difference in CfP 1 BI expression may be cell line- or 
cell culture- condition mediated. As another possible difference, we noticed that the 
endocrine resistant cell lines used in the previous report were supplemented with 
insulin [315], whereas we do not supplement our cell culture media with insulin. 
Although studies in diabetic rats indicate that insulin represses hepatic CfP 1 BI [316], 
the regulation of CfPIBI by insulin in breast cancer cells has not, to our knowledge, 
been examined. CfPIBI mRNA expression was higher in MCF-7 than LY2 cells, 
but was not significantly regulated by E2 or 4-0HT with 6 h treatment in MCF-7 cells. 
These data reflect previous findings regarding detection of CfP 1 BI expression in 
MCF-7 cells [317]. We did not detect an increase in CfPIBI with 6 h of treatment, 
as reported for 12 h of E2 treatment in MCF- 7 cells [318]. The reduction of miR-
200b and miR-200c detected with 4-0HT treatment in MCF-7 cells in micro array 
(Figure 3) would be expected to increase targets of these miRNAs, including 
CfPIBI. Indeed, CfPIBI mRNA was increased in the micro array study with 8 h of 
64 
1 11M 4-0HT treatment (Appendix 2) [310]; but after 6 h of treatment, no reduction in 
CYP1Bl was detected. 
ERBB3 is an oncogene that is a member of the epidermal growth factor 
receptor (EGFR) family of transmembrane tyrosine kinases that is bound by heregulin 
and is involved in the pathogenesis and progression of breast cancer [319]. ERBB3 is 
frequently over-expressed in breast cancer and increased in TAM resistance 
[319,320]. ERBB3 is a putative target of miR-22, miR-125b, miR-221, miR-222, 
miR-93 according to our bioinformatic analyses and is a bone fide target of miR-125b 
[201]. Increased expression of these miRNAs in LY2 cells would be expected to 
reduce the expression of ERBB3 in L Y2 cells. In agreement with this idea, we did not 
detect ERBB3 mRNA in L Y2 cells, even when treated with 4-0HT (Figure 10B and 
data not shown). We did not detect regulation of ERBB3 mRNA by E2 or 4-0HT 
with 6 h treatment in MCF-7 cells. Others reported that ERBB3 mRNA was inhibited 
by 48 h treatment of MCF-7 cells with 1 nM E2 and this inhibition blocked by 1 11M 
TAM in MCF-7 cells [321]. The difference in time of treatment is likely responsible 
for differences in ERBB3 regulation. 
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Figure 9: miR-21 target genes expression in MCF-7 and LY2 cells. MCF-7 and 
L Y2 cells were serum-starved for 48 h and then treated with EtOH, 10 oM E2, or 100 
oM 4-0HT for 6 h prior to RNA isolation (A) or 24 h prior to WCE preparation (B) as 
described in Materials and Methods. (A) Q-PCR was performed for the indicated 
genes and fold-expression determined compared to EtOH as described in Materials 
and Methods. Values are the average of 3 separate determinations ± SEM. (B) 
Western blot for the indicated proteins. The membrane was stripped and repro bed for 
a-tubulin for normalization as described in Materials and Methods. The blot shown is 
representative of three separate biological replicates. 
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ESRt and ERa protein expression is lower in L Y2 than MCF -7 cells 
MiR-221 and miR-222 expression was higher in LY2 compared to MCF-7 
cells. miR-221 and miR-222 are overexpressed in ERa-negative and TAM-resistant 
breast cancer cell lines [270,295]. Knockdown of miR-221 and miR-222 in MDA-
MB-468 breast cancer cells partially restored ERa expression and TAM-sensitivity 
[295]. ESRl mRNA expression is lower in LY2 than MCF-7 cells (Figure 1OC). 
Western confirmed lower ERa protein expression in LY2 cells when compared to 
MCF-7 cells (Figure 4F). These data agree with reports that miR-2211222 is 
overexpressed in TAM-resistant breast cancer cell lines and suppresses ERa 
expression. 
miR-200-regulated ZEDt is reduced in L Y2 cells 
miR-200 family members suppress expression of the transcription factor 
ZEB 1 that initiates epithelial to mesenchymal transition (EMT) by repressing 
transcription of E-cadherin and other genes regulating cell polarity [203,205,322-
326]. Because all three miR-200 family members were expressed at significantly 
lower levels in L Y2 than MCF-7 cells, we examined ZEB 1 as a miR-200 target in 
MCF-7, LCCl, LCC2, LCC9, LY2, and MDA-MB-231 breast cancer cells by western 
blot (Figure llA). LCCI are estrogen-independent derivatives of MCF-7 cells and 
LCC2 and LCC9 are also endocrine-resistant derivatives of MCF-7 cells [278]. 
MDA-MB-231 serve as a positive control since ZEB 1 expression is higher in MDA-
MB-231, but not in MCF-7 [327]. As expected, ZEBI was not expressed in MCF-7, 
but was expressed in MDA-MB-231 (Figure 11A). LY2 cells express ZEBl, 
indicating that this cell line has undergone EMT. However, LCCl, LCC2, and LCC9 
cells do not express ZEB 1, indicating that these estrogen-independent (LCCl) and 
tamoxifenlendocrine-resistant (LCC2 and LCC9) cell lines have not undergone EMT. 
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Because E-cadherin is inversely correlated with ZEB 1 expression and inversely 
correlated with miR-200c [324], we examined E-cadherin in MCF-7, LY2, and 
MDA-MB-231 cells (Figure lIB). E-cadherin was not expressed in LY2 or MDA-
MB-231 cells, indicating that LY2 cells have undergone EMT. This is, to our 
knowledge, the first demonstration of EMT in the L Y2 endocrine-resistant breast 
cancer cell line. 
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Figure 10: CYP1B1, ERBB3, and ESR1 gene expression in MCF-7 and LY2 
cells. MCF-7 and L Y2 cells were serum-starved for 48 h and then treated with EtOH, 
10 nM E2, or 100 nM 4-0HT for 6 h prior to RNA isolation (A) or 24 h prior to WCE 
preparation (B) as described in Materials and Methods. Q-PCR was performed for the 
indicated genes and fold-expression determined compared to EtOH as described in 




















ERBB3 in MCF-7 
Figure 11: ZEBl and E-cadherin expression. Whole celllysates or nuclear extracts 
were prepared from the indicated breast cancer cell lines. Identical amounts (30 )lg) 
of protein were immunoblotted for ZEB I and E-cadherin as described in Materials 
and Methods. The membranes were stripped and reprobed for ~-actin. These blots 
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CHAPTER IV: REDUCED EXPRESSION OF MIRNA-200 FAMILY IN LY2 
CELLS CONFERS RESISTANCE TO TAMOXIFEN AND FULVESTRANT 
1. INTRODUCTION 
As previously discussed in earlier chapters, miRNAs regulate gene expression 
at the post-transcriptional level [328]. miRNAs are aberrantly expressed in different 
types of cancer including breast cancer [197]. 
EMT (epithelial-to-mesenchymal transition) is a hallmark of metastatic cancer [329]. 
EMT is induced by several signaling pathways such as TGF-~, Wnt and Notch 
[330,331]. It is characterized by loss of the epithelial marker E-cadherin due to gene 
methylation or repression by upregulation of transcription factors Zinc finger E-box 
binding homeobox domain proteins such as ZEB 1 (also known as TeFl or ~EF1) or 
ZEB2 (also known as SIP1), Snail1l2 and TWIST that repress E-cadherin in epithelial 
cells [332-335]. As a result, cells acquire a mesenchymal phenotype characterized by 
the expression of markers such as vimentin and N-cadherin [336]. Reduced 
expression of miRNA-200 and miR-205; and increased expression miR-2211222 are 
implicated in EMT and metastasis [337]. Aberrant expression of these miRNAs has 
been reported to increase metastatic breast cancer [338,339]. The link between the 
development of endocrine resistance and EMT in breast cancer is still not clearly 
understood. Studies have shown that endocrine resistance confers metastatic 
properties to cells. For example, some endocrine-resistant cells and tumors show 
activation of the ~-catenin pathway and induction of Snail and TWIST that contribute 
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to EMT by repressing E-cadherin transcription [340-342]. A few studies have shown 
that miRNAs have a role in conferring endocrine-resistance which subsequently led to 
induction of EMT and metastasis. For example, re-expression of miR-375 restored 
TAM sensitivity and reverted EMT in breast cancer cells [343]. Prolonged growth of 
MCF-7 breast cancer cells as mammospheres induced EMT and resistance to TAM 
[344]. Notably, these MCF-7 mammospheres exhibited higher expression of miR-
2211222 and reduced expression of miR-200c, miR-203 and miR-205 compared to 
MCF-7 cells [344]. 
The miR-200 family of miRNAs are derived from two chromosomal locations: 
miR-200b, miR-200a, and miR-429 are located on chromosome 1 p36; miR-200c and 
miR-141 are located on 12p13 [203]. The miR-200bc/429 cluster differs from the 
miR-200a/141 cluster by the fourth nucleotide (U to C) in the seed region and this 
means that they regulate different genes in breast cancer [206]. Reduced expression 
of miR-200 family of miRNAs has been observed in breast, ovarian, endometrial, 
lung and gastric cancers compared to normal tissue [322]. Many studies have 
identified an inverse relationship between the expression of miR-200 family and its 
targets ZEB I in cells [205,345-347]. We recently reported increased expression of 
ZEB 1 protein and loss of its target E-cadherin in an endocrine-resistant cell line L Y2 
compared to parental MCF-7 human breast cancer cells[247]. We observed that the 
L Y2 cell line had undetectable levels of miR-200 family members compared to the 
parental MCF-7 cell line, suggesting a role for miR-200 in tamoxifenlendocrine-
resistance and loss of ZEB I repression. 
Here I examined the expression of miR-200a, miR-200b, and miR-20Oc and 
their regulation by E2 and 4-0HT, an active TAM metabolite in a panel of ERa 
positive breast cancer cell lines representing progreSSIOn towards 
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endocrine/tamoxifen-resistance. Further, I tested how overexpression of miR-200b 
and miR-200c affected LY2 cell morphology, expression of ZEBI and vimentin, and 
cell proliferation. I also examined how knockdown of miR-200b and miR-200c 
affected the sensitivity of MCF-7 cells to TAM and fulvestrant. Lastly, I examined if 
epigenetic modification of miR-200b and miR-200c could be responsible for the 
lower expression of these miRNAs in L Y2 cells compared to the parental MCF-7 
cells. 
2. MATERIALS AND METHODS 
Cell culture 
MCF-7 human breast cancer cells were purchased from ATCC (Manassas, VA, USA) 
and maintained in IMEM supplemented with lO% fetal bovine and 1 % 
penicillin/streptomycin (Invitrogen, Carlsbad, CA, USA) serum [203]. LCCl, LCC2, 
LCC9, and L Y2 are derivatives of MCF-7 cells that are E2, tamoxifen, and multiple 
SERM-independent, respectively, and were graciously provided by Dr. Robert Clarke, 
Georgetown University. Prior to treatment, the medium was replaced with phenol 
red-free IMEM supplemented with 5% dextran charcoal-stripped FBS and 1 % 
penicillin/streptomycin (stripped medium) or 48 h (referred to as 'serum-starving'). 
Chemicals 
E2 and 4-0HT were purchased from Sigma-Aldrich (St. Louis, MO). ICI 182,780 
was from Tocris (Ellisville, MO). Cells were treated with ethanol (EtOH, the vehicle 
control, 0.01 % final volume) 10 nM E2 or 100 nM 4-0HT for 6 h as indicated. Where 
indicated LY2 cells were treated with 2.5 IlM 5-aza-2'-deoxycytidine (5-aza-dC, 
Sigma-Aldrich, St. Louis, MO) alone or in combination with 100 ng/Ill Trichostatin A 
(TSA, Sigma-Aldrich) for 72 h, with TSA added 16 h prior to RNA extraction. 
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RNA isolation and quantitative Real-Time-PCR (Q-PCR) for miRNA and 
mRNA expression 
miRNA-enriched total RNA was extracted from MCF-7 and LY2 cells treated as 
above using the miRNA isolation kit (Exiqon, Woburn, MA). The quality and 
quantity of the isolated RNA was analyzed using a NanoDrop spectrophotometer. 
cDNA was synthesized using the miRCURY LNATM first strand cDNA synthesis kit 
(Exiqon) and Q-PCR was performed using the miRCURY LNA ™ SYBR Green 
master mix (Exiqon) using the miRNA primer sets for miR-200a, miR-200b or -miR-
200c (Exiqon). SNORD38D, SNORD48 and 5SRNA were used for normalization of 
miRNA expression. Analysis and fold change was determined using the comparative 
threshold cycle (Ct) method. The change in miRNA expression was calculated as 
fold-change, i.e., relative to EtOH-treated (control). 
For mRNA expression, the High Capacity cDNA Reverse Transcription kit (PE 
Applied Biosystems) was used to reverse transcribe total RNA using random 
hexamers. Q-PCR for ZEBI was performed using SYBR green in the ABI PRISM 
7900 SDS 2.1 (PE Applied Biosystems,Carlsbad, CA) using relative quantification. 
The sequence of ZEB 1 primers is described in [205]. Analysis and fold differences 
were determined using the comparative CT method. Fold change was calculated from 
the MCT values with the formula 2-MCT and data are relative to EtOH-treated cells. 
Transient transfection 
MCF-7 or L Y2 cells were transfected with either anti-miRNAs (antimiRs, Ambion, 
Life Technologies, Carslbad, CA) or precursor microRNA (pre-miRs, Ambion) 
respectively for miR-200b or miR-200c using Lipofectamine RNAimax (Invitrogen) 
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reagent. After 1 or 5 d, RNA was isolated (as described above) to confirm knockdown 
or overexpression of miR-200b or miR-200c. 
MTTassay 
MCF-7 or L Y2 cells were grown in 96 well plates. Following transfection with anti-
miRs or pre-miRs respectively for 24 h or 5 days, cells were treated with vehicle 
control EtOH, 10 nM E2, 100 nM or I f.lM 4-0HT, 100 nM or I f.lM fulvestrant for 4 
or 6 days. 20 f.ll of Cell Titer reagent (Promega, Madison, WI) was added to the wells 
and absorbance was read at 490 nm using a spectrophotometer (SpectraMax M2, 
Molecular Devices, Sunnyvale, CA). 
Whole cell preparation for western blotting 
Whole cell lysates were prepared and western blots were performed as described in 
[161]. Protein concentrations were determined by BioRad DCC protein assay 
(Hercules, CA). 
Antibodies and reagents 
Antibodies were purchased as follows: E-cadherin (Cell Signaling, Danvers, MA), 
vimentin (Santa Cruz Biotechnology, Santa Cruz, CA), p-actin (Sigma-Aldrich). 
Chemiluminescent bands on the PVDF membranes were visualized on a Kodak 
Carestream Imager using Carestream Molecular Imaging software (New Haven, CT). 
Microscopy images 
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LY2 cells were untransfected or transfected with pre-miR-200b or pre-miR-200c or 
negative control for 48 h (described above). Images were captured using a digital 
microscope (EVOS, AMG, Bothell, W A) at a magnification of 20x and 1 00 ~m scale. 
Statistical analysis 
Statistical evaluations were performed using GraphPad PRISM. Student's t-test was 
used to compare control and treatment values. P-values indicate statistical 
significance. 
3. RESULTS 
Expression of miR-200 family in MCF-7, LCCl, LCC2, LCC9 and LY2 human 
breast cancer cells 
Microarray analysis of miRNA expression revealed low miR-200a, miR-200b 
and miR-200c expression in L Y2 endocrine-resistant breast cancer cells compared to 
MCF-7 endocrine-sensitive breast cancer cells [161]. To follow up on this initial 
observation, the expression of miR-200a, miR-200b and miR-200c was measured by 
Q-PCR in a panel of human breast cancer cell lines, i.e., MCF-7 cells and LCCl, 
LCC2 and LCC9 cells that were derived from the parental MCF-7 cell line by 
propagation in mice (LCC I), and then in long-term culture with tamoxifen (LCC2) or 
fulvestrant (LCC9) [348]. L Y2 tamoxifenlfulvestrant-resistant human breast cancer 
cells were independently derived from MCF-7 cells by culture in a precursor to 
raloxifene: LY 117018 [349]. LY2 are cross-resistant to TAM, raloxifene, fulvestrant 
(Faslodex or ICI 182,780), and are ERa positive, although ERa protein expression is 
lower than MCF-7 cells [247]. These cells represent a model of the progression of 
breast cancer cells towards TAM/endocrine-resistance. 
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The effect of E2 and 4-0HT on miR-200 expression was examined by Q-PCR 
III the cell lines described above (Figure 12). 10 nM E2 and 100 nM 4-0HT 
significantly decreased miR-200a and miR-200b expression in MCF-7 cells. 
Similarly, E2 significantly decreased the expression of miR-200a, miR-200b and miR-
200c in estrogen-independent, but tamoxifen-sensitive LCCI cells. However, there 
was no effect of E2 and 4-0HT on the expression of miR-200 family in LCC2 and 
LY2 (Figure 13A-C). In LCC9, E2 and 4-0HT decrease miR-200a and miR-200b 
expression and 4-0HT decreases miR-200c expression. LCCI cells showed highest 
basal miR-200a expression. L Y2 cells had undetectable levels of miR-200 family 
expression (Figure 12A-C). This is the first report of 4-0HT regulation of miR-200 
family expression in LCC 1, LCC2, LCC9 and L Y2 cells. We and others previously 
reported that E2 reduces miR-200 family expression in MCF-7 cells [159,161] 
E2 and 4-0HT regulate ZEBt in MCF-7, LCCt, LCC2, LCC9 and LY2 human 
breast cancer cells 
miR-200 family members repress ZEB 1 [203,322,345]. Next we evaluated 
ZEB 1 mRNA expression in each cell line. Basal expression of ZEB 1 was lower in 
LCCI, LCC2, and LCC9 compared to MCF-7 (Figure 14A). As previously reported, 
ZEB 1 expression was higher in L Y2 compared to MCF-7 [247]. E2 and 4-0HT 
decreased the expression of ZEBI in MCF-7 cells (Figure 14A). There was no 
significant effect of either E2 or 4-0HT on ZEB 1 expression in LCC 1, LCC2, or 
LCC9 cells (Figure 14B). In contrast, in LY2 cells, E2 increased the expression of 
ZEB 1 mRNA. Notably, there is an inverse relationship between the expression of 
miR-200 family and ZEB 1 in LY2 cells (compare Figures. 12 and 14A). 
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Figure 12: Q-PCR analysis of the expression of miR-200 family in MCF-7, 
LCC1, LCC2, LCC9 and L Y2 cells. Cells were treated with vehicle control EtOH, 
or 10 nM ~ or 100 nM 4-0HT for 6 h. Values are the average of 3-4 experiments 
normalized to 5SrRNA or SNORD38D or SNORD48 and are expressed as fold 
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Figure 13: Q-PCR analysis of the expression of miR-200 family in MCF-7, 
LCCl, LCC2, LCC9 and L Y2 cells. Cells were treated with vehicle control EtOH, 
or 10 nM E2 or 100 nM 4-0HT for 6 h. Values are the average of 3-4 experiments 
normalized to 5SrRNA or SNORD38D or SNORD48 and are expressed as fold 
relative to EtOH-treated expression for each cell line. * p<0.05 versus EtOH treated 































































Figure 14: Q-PCR analysis of the expression of ZEB1 mRNA in MCF-7, LCC1, 
LCC2, LCC9 and L Y2 cells. Cells were treated with vehicle control EtOH, or 10 nM 
E2 or 100 nM 4-0HT for 6 h. A. Values are the average of 3-4 experiments 
normalized to GAPDH and are expressed as fold relative to EtOH-treated MCF-7 
expression for each cell line. *p<0.05 significantly different from MCF-7 EtOH 
treated. B. Values are the average of 3-4 experiments normalized to GAPDH and are 
expressed as fold relative to EtOH-treated for each cell line. *p<0.05 significantly 
different from EtOH treated for each cell line. 
15 
A * Cl EtOH c 14 
0 13 * E2 CI) 







MCF-7 LCC1 LCC2 LCC9 LY2 
c CEtOH 
o 1.6 B - E2 ·iii 










MCF-7 LCC1 LCC2 LCC9 LY2 
82 
Overexpression of miR-200b or miR-200c in L Y2 cells enhanced their sensitivity 
to 4-0HT or fulvestrant 
To examine if expression of miR-200 family members affects sensitivity of 
endocrine-resistant L Y2 cells to antiestrogens, cells were transiently transfected with 
precursors for miR-200a, miR-200b and miR-200c and MIT cell viability assays 
were performed in cells treated with vehicle control, 4-0HT, or fulvestrant for 6 days. 
Increased miR-200a, miR-200b and miR-200c expression was confirmed by Q-PCR 
even 7 days after transfection (Figure 15A). Treatment of nontransfected or control 
miRNA-transfected L Y2 cells with 4-0HT or fulvestrant had no effect on cell 
viability (Figure 16A). L Y2 cell viability was unaffected by overexpression of miR-
200a regardless of treatment (Figure 16A). Overexpression of miR-200b increased 
LY2 cell sensitivity to inhibition by 4-0HT and fulvestrant. Overexpression of miR-
200c reduced basal L Y2 viability and fulvestrant, but not 4-0HT, further inhibited 
L Y2 viability. 
To determine if a shorter time of pre-miR-200b and pre-miR-200c transfection 
increases sensitivity of L Y2 cells to inhibition by 4-0HT and fulvestrant, cells were 
transfected with pre-miR-200b or pre-miR-200c for 24 h and then treated with higher 
concentrations of 4-0HT and fulvestrant for 4 days. Q-PCR confirmed miR-200b and 
miR-200c overexpression in the transfected cells 5 dafter transfection (Figure 15B). 
Notably the level of miR-200b was higher after 7 d than 5 d. Cell viability assays 
demonstrated lower basal level of proliferation in cells overexpressing miR-200b or 
miR -200c regardless of treatment (Figure 16B). 
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Figure 15: Overexpression of miR-200b or miR-200c in L Y2 cells transfected 
with pre-miR-200b or pre-miR-200c or negative control. L Y2 cells were 
transfected either with negative control or pre-miR-200a, pre-miR-200b or pre-miR-
200c. RNA was harvested at 5 or 7 days and Q-PCR performed to confirm 
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Figure 16: Overexpression of miR-200b or miR-200c restores sensitivity of LY2 
cells to 4-0HT and fulvestrant. A. LY2 cells were either untransfected (No TF) 
transfected with negative control (Neg control) or pre-miR-200a, miR-200b or miR-
200c. 5 days post-transfection, cells were starved for 24 h and treated with 100 nM 4-
OHT or 100 nM fulvestrant for 6 days *p<0.05 versus L Y2 EtOH treated negative 
control. # p<0.05 versus LY2 EtOH treated for each miRNA. B. L Y2 cells were 
either untransfected (No TF) or transfected with pre-rniR-200b or rniR-200c. 1 day 
post-transfection, ceIJs were treated with 1 J..LM 4-0 HT or 1 J.LM fulvestrant for 4 days 
and MTT assays were performed. Values are the mean ±SEM of 3 
experiments . *p<0.05 versus L Y2 EtOH treated No TF. 
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Converse experiments were performed using anti-miRNA to knockdown the 
expression of miR-200b or miR-200c in MCF-7 cells (Figure 17 A and B). 
Surprisingly, knockdown of miR-200b and miR-200c reduced basal MCF-7 cell 
viability. However, there was no change in the sensitivity of cells to 100 nM 4-0HT 
or fulvestrant after knockdown of miR-200b or miR-200c (Figure 17C) in MCF-7 
cells, indicating that other factors also contribute to the sensitivity of breast cancer 
cells to antiestrogens. 
Overexpression of miR-200b or miR-200c changes morphology of L Y2 cells to a 
'cobblestone' shaped appearance 
Overexpression of miR-200b and miR-200c (Appendix SA) altered LY2 cell 
morphology (Figure IS). L Y2 cells showed a change from an elongated to a more 
epithelial or 'cobble-stone' shaped appearance (Figure ISC and D). Overexpression 
of miR-200a had no effect on LY2 cell appearance, in agreement with the lack of 
effect of miR-200a on cell viability (Figure ISB). Overexpression of a control 
miRNA had no effect on cell appearance (Appendix SB). Previous studies have 
reported the reversal of EMT in MDA-MB-231 breast cancer cells with miR-20Oc 
overexpression of [347]. These results are in agreement with my study and indicates 
that LY2 cells undergo change in morphology upon overexpression of miR-200b or 
miR-200c. 
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Figure 17: Knockdown of miR-200b or miR-200c does not promote resistance of 
MCF-7 to 4-0HT or fulvestrant. 
MCF-7 cells were either transfected with anti-miR -200b or anti-miR-200c. 1 day 
post-transfection, cells were treated with 100 nM 4-0HT or 100 nM fulvestrant for 4 
days and MIT assays were performed. Va1ues are the mean ±SEM of 3 experiments. 
*P<0.05 versus EtOH treated (miR-200b). # p<0.05 versus EtOH treated (rniR-200c) 
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To confirm if the observed change in morphology of L Y2 cells was due to 
reduced expression of mesenchymal markers, vimentin protein was examined in cells 
expressing transfected with miR-200b or miR-200c. Overexpression of miR-200b or 
miR-200c in LY2 cells did not induce MET (mesenchymal- to - epithelial transition) 
as indicated by unaltered vimentin or E-cadherin expression in cells transfected with 
miR-200b or miR-200c (Figure 18E). However, there was a decrease in ZEB I 
mRNA in cells transiently overexpressiong miR-200a, miR-200b or miR-200c (Figure 
18F). These results indicate that factors other than the reduction of miR-200b and 
miR-200c contribute to EMT in L Y2 cells. 
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Figure 18: Overexpression of miR-200 family changes morphology of L Y2 cells. 
LY2 cells were transfected with pre-miR-200a, or pre-miR-200b or pre-miR-200c for 
3 days. A-D. Images of L Y2 cells captured using a digital microscope (20x 
magnification, bar-lOO Ilm scale). E. Expression of vimentin protein in cells 
expressing miR-200a, miR-200b or miR-200c. Images and Western blots are 
representative of 3 separate experiments. F. Expression of ZEB 1 mRNA in L Y2 cells 
expressing miR-200a, miR-200b or miR-200c or negative control. Results are the 
mean ±SEM of two separate experiments. 
A. No transfection B. miR-200a 
C. miR-200b D. miR-200c 
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Inhibitors of deacetylation and methylation increase miR-200 family expression 
in LY2 cells 
One possible mechanism responsible for reduced expression of miR-200 
family members in L Y2 cells could be DNA methylation or histone deacetylation. 
Previous studies have shown that the CpG island near the miR-200c/miR-141 
transcription start site is methylated in fibroblasts and tumors cells that are miR-200c 
or miR-141-negative [350,351]. To determine if decreased expression of miR-200 
family members in L Y2 cells is due to epigenetic silencing, L Y2 cells were treated 
with 2.5 11M 5-aza-dC alone in combination with 100 ng/1l1 trichostatin A (TSA), a 
histone deacetylase (HDAC) inhibitor for 72 h. TSA was added in the last 16 h of the 
treatment period [352]. 2.5 11M 5-aza-dC and TSA increased the expression of miR-
200b and miR-200c in LY2 cells (Figure 19A and B). Concomitant with the 
increased expression of miR-200b and miR-200c, there was a decrease in expression 
of its target, ZEB 1 mRNA upon combined treatment with 2.5 11M 5-aza-dC and TSA 
(Figure 19C). To determine if the observed decrease in ZEB 1 mRNA level is due to a 
direct effect of the inhibitors, MCF-7 cells were treated with 2.5 11M 5-aza-dC alone 
or in combination with 100 ng/1l1 TSA. Combined treatment with 5-aza-dC and TSA 
did not alter the expression of ZEB 1 in MCF-7 cells (Figure 19F). However, it 
increased the expression ofmiR-200b and miR-200c in MCF-7 cells (Figure 19D and 
E). 
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Figure 19: 5-aza-dC and TSA co-administration results in an increase in miR-
200b and miR-200c expression, and a concomitant decrease in ZEB1 mRNA in 
L Y2 cells. A-C. L Y2 cells were treated with 2.5 11M 5-aza-dCA in combination with 
100 ng/1l1 TSA for 72 h. TSA was added only during the last 16 h of treatment. Q-
PCR was used to determine the fold change in the expression of miR-200b, or miR-
200c, or ZEB 1 mRNA. A an C are the mean ± SEM of 2 separate experiments. B is 
the mean of triplicate determinations in one experiment. D-F. MCF-7 cells were 
treated with 2.5 11M 5-aza-dCA alone or in combination with 100 ng/1l1 TSA for 72 h. 
TSA was added only during the last 16 h of treatment. Q-PCR was used to determine 
the fold change in the expression of miR-200b, or miR-200c or ZEB 1 mRNA. Values 
are the average of triplicate determinations in one experiment. 
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In this study I identified a novel role for miR-200b and miR-200c in 
modulating the sensitivity of endocrine-resistant L Y2 cells to 4-0HT and fulvestrant 
in addition to the previously reported ability of these miRNAs to stimulate EMT. A 
progressive decrease in the expression of miR-200a, miR-200b, and miR-200c was 
detected in an MCF-7 -derived cell line model of tamoxifenlendocrine resistance. The 
parental estrogen- dependent, endocrine-sensitive MCF-7 cells express all three miR-
200 family members. With the LCC2, LCC9, and L Y2 cells derived for progressive 
tamoxifen and fulvestrant resistance, I observed a graded reduction in miR-200 family 
expression (Figure 12 A-C). 
This is the first report demonstrating that overexpression of miR-200b and 
miR-200c enhanced the sensitivity of breast cancer cells to growth inhibition by 
antiestrogens 4-0HT and fulvestrant. Here I demonstrated that overexpression of 
miR-200b or miR-200c for 11 days increased sensitivity of LY2 cells to 100 nM 4-
OHT and fulvestrant (Figure 16A). A shorter 5 day period of overexpression of miR-
200a and miR-200b reduced basal LY2 cell viability independent of antiestrogen 
treatment (Figure 16B). One possible explanation for these different results is lower 
levels of miR-200b and miR-200c in cells after longer periods of transfection. Hence 
the decrease in basal cell viability in the control treated cells may be due to higher 
miR-200b and miR-200c levels at earlier times after transfection. This result may 
explain why no additional inhibitory effect of 4-0HT on cell viability was detected. 
A role for miR-200 family in drug resistance was reported in ovarian cancer 
[323]. Overexpression of miR-200c increased the sensitivity of ovarian cancer cells 
to a microtubule targeting drug Paclitaxel [323]. This was mediated by miR-200c 
targeting of a microtubule associated protein TUBB3. Overexpression of miR-200c 
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reversed resistance of UMUC3 bladder cancer cells to anti-EGFR therapy [353]. 
Similarly gemcitabine-resistance in pancreatic cancer is associated with decreased 
miR-200 expression [354]. Resistance of pancreatic cancer cells to gemcitabine was 
reduced by treatment with natural compounds such curcumin, alone or in 
combination. This was accompanied by increased miR-200 expression [353,355-
357]. CDF, an analogue of curcumin was found to increase the sensitivity of 
pancreatic cancer cells to gemcitabine through inactivation of NFkB and COX-2 
pathways which led to increased expression of miR-200b and miR-200c [356]. 
These studies show that miR-200 has a dual role in drug resistance. 
Our results show that there is an inverse relationship between the expression 
of miR-200 family (miR-200a, miR-200b and miR-200c) and ZEB1 mRNA in LY2 
cells. These data are in agreement with other reports showing an inverse correlation 
between miR-200 family and ZEB 1 expression in basal-like, TNBC cells such as 
MDA-MB-231 and BT-549 cell lines [203,205,345,347]. 
LY2 cells overexpressing miR-200b or miR-200c showed a change in 
morphology from a 'cobblestone' or mesenchymal phenotype to a spindle shaped or 
epithelial phenotype (Figure 18C and D). However cells expressing miR-200a did not 
show a change in morphology or change in sensitivity to antiestrogens (Figure 16A 
and 18B). miR-200b and miR-200c share the same seed sequence [206]. The 
similarity in effects of these miRNAs can be attributed to this identical seed sequence 
of miR-200b and miR-200c. These results indicate a novel role for miR-200b and 
miR-200c in cellular morphology and response to 4-0HT and fulvestrant. Other 
studies have observed a reversal of EMT in aggressive breast cancer cell lines 
transfected with miR-200c or miR-141 [203,205,346,347]. For example, 
overexpression of miR-200b and miR-200c reverted EMT in mesenchymal breast 
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cancer cell lines MDA-MB-231 and BT -549 by repressing the transcription and 
translation of transcription factors ZEB 1 and ZEB2 [205,325]. Similar results were 
observed in miR-200b and miR-200b transfected MDCK- Paz (Madin-Darby canine 
kidney cells) [203]. Likewise, ectopic expression of miR-20Oc restored E-cadherin 
expression and reversed the mesenchymal phenotype in NMuMG (normal murine 
mammary epithelial cells) and 4T07 breast carcinoma cell lines that had undergone 
EMT [346]. Our data showing a change in morphology of LY2 cells overexpressing 
miR-200b and miR-200c are in agreement with these observations, although we did 
not detect a reduction in vimentin or an increase in E-cadherin protein expression 
(data not shown). 
One of the mechanisms for decreased miR-200 expression in LY2 cells could 
be due to epigenetic changes in the promoter, e.g., DNA methylation and histone 
de acetylation. CpG island methylation of miR-200c/miR-141 promoter has been 
previously reported in breast and prostate cancer cells [350,351,358]. Treatment of 
MDA-MB-231 and BT549 breast and PC3 prostate cancer cells with 3 J..lM 5-aza-dC, 
an inhibitor of DNA methylation, increased miR -200c and miR -141 expression [350]. 
Analysis of histone modification by chromatin immunoprecipitation (ChIP) revealed 
dimethylation of Lysine 9 of histone H3 in miR-200c/miR-141-negative MDA-MB-
231 breast cancer cells, indicating repression of the miR-200c/miR-141 cluster. The 
data provided in this chapter agrees with these reports of epigenetic silencing of the 
miR-200 family. I demonstrated that treatment of LY2 cells with 2.5 J..lM 5-aza-dC in 
combination with TSA increased miR-200b and miR-200c expression when compared 
to untreated cells (Figure 19). There was a concomitant decrease in the expression of 
ZEBI mRNA. 
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Previous studies have shown that endocrine resistance is accompanied by loss 
of cell-to-cell adhesion and EMT. Hiscox et al. showed that induction of EMT in 
MCF-7 breast cancer cells that are tamoxifen- resistant (TAM-R), is due to EGFR 
mediated phosphorylation and activation of the ~-catenin pathway [340]. This 
promotes EMT and subsequently metastasis of cancer cells. Another study by the 
same group demonstrated that fulvestrant-resistant MCF-7 and T47D cells show 
enhanced migration and invasion due to overexpression of the c-Met receptor protein 
[359]. Further, elevated Src activity was also found to contribute to the invasive 
phenotype of TAM-R MCF-7 cells [360]. A recent study shows that prolonged 
mammosphere culture of MCF-7 cells makes them metastatic as well as resistant to 
tamoxifen [361]. Induction of Snail I transcription factor promotes EMT in MCF-7 
TAM-R cells by downregulation of the epithelial marker E-cadherin [341]. This 
effect was seen upon overexpression of a peptidyl-prolyl isomerase Pinl which, in 
tum, activates GSK-3~ or NF1d3. These reports indicate a link between aberrant 
activation of signaling pathways such as NF1d3 to EMT and endocrine resistance. 
However, there is only one report of miRNA regulation of both EMT and endocrine-
resistance in breast cancer cells [343]. That study showed that overexpression of miR-
375 increased sensitivity of TAM-R MCF-7 cells to treatment with TAM by 
decreasing the expression of Metadherin (MTDH). My identification of reduced miR-
200 expression as a marker of endocrine resistance of breast cancer cells is a novel 
finding. 
Although miR-200 is considered as a tumor suppressor miRNA, there are 
some reports of its role as an oncogene. There are many reports of miR-200 family 
expression as a marker of poor prognosis and chemoresistance in ovarian cancer [362-
364]. Contrary to the expected decrease in miR-200 expression in metastatic cells, 
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Dykxhoorn et al. observed high levels of miR-200b and miR-200c in 4Tl metastatic 
mouse mammary tumor cells [365]. In concordance, 4Tl cells showed low ZEB 1 and 
high E-cadherin expression. These results indicate that mR-200 has a dual pattern of 
expression, i.e., it suppresses EMT while it promotes metastatic colonization after 
cells have invaded a distant site. Further, Korpal et al. reported pro-metastatic effects 
of miR-200 in a mouse model of breast cancer metastasis [366]. miR-200 was found 
to target Sec23a, a suppressor of metastasis that regulates the cell-secretome. These 
studies shed light on the dual role of miR-200 depending on the cell context. 
In summary, the results presented in this chapter reveal a novel role for the 
loss of miR-200b and miR-200c in contributing to the loss of antiestrogen sensitivity 
in endocrine resistant breast cells. Of course, additional factors are also involved. 
Although most studies have identified a role for miR-200 as a suppressor of EMT, my 
studies provide new evidence (Fig.16A) to show miR-200 as a suppressor of 
endocrine resistance in breast cancer cells. Future experiments are needed to assess 
the dual role of miR-200b and miR-200c in cancer progression so that appropriate 
targets can be used for targeted therapy. This would enable the use of this miRNA as 
a marker of endocrine-resistant breast cancer. 
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Figure 20: Proposed model of miR-200 function in endocrine-resistant breast 
cancer. In endocrine-sensitive breast cancer, miR-200 suppresses ZEB 1 expression 
and promotes an epithelial phenotype. Decreased expression of miR-200 family in 
endocrine-resistant breast cancer is a result of DNA methylation, and results in 
increased ZEB 1 expression and a change in morphology of cells from an epithelial to 
a mesenchymal appearance. 
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CHAPTER V: RESEARCH IMPLICATIONS 
Adjuvant endocrine therapy is widely used in the treatment of premenopausal 
and postmenopausal women with ER-positive breast cancer. It involves the use of 
SERMs, e.g., TAM, Raloxifene, and pure antiestrogens, e.g., fulvestrant, that interfere 
with estrogen receptor function [248,367]. However, about 40 % of women who 
receive adjuvant hormonal therapy acquire endocrine resistance [56]. Aberrant 
activation of growth factor signaling pathways, such as the EGFR, and the mutant 
EGFR (Her2), and altered expression of co-regulators are some of the mechanisms 
involved in endocrine resistance [368]. However, the complexity of endocrine 
resistance remains to be fully elucidated. My dissertation focused on identifying 
miRNAs that are aberrantly expressed in endocrine-resistant breast cancer. 
Deregulated expression of miRNAs has been reported in a number of cancers and 
these small RNAs are becoming increasingly important players affecting different 
signaling pathways [262]. By identifying miRNAs that are dysregulated in endocrine-
resistant breast cancer, it is possible to test their use as markers of resistance. 
One major finding of my study is that there is an opposite pattern of 
expression of miRNAs in antiestrogen-sensitive MCF-7 vs. -resistant L Y2 cells. In 
Chapter III, I identified 97 miRNAs that are significantly differentially expressed in 
MCF-7 and L Y2 cells. This is a significant finding as it shows that acquisition of 
endocrine resistance is associated with altered miRNA signature. Results from this 
chapter are important as this is one of the few studies that have profiled miRNAs in 
endocrine-resistant breast cancer cells. 
100 
My study identified reliable endogenous control genes (ECGs) for 
normalization of miRNA Q-PCR data. Identification of an ideal ECG for 
normalization of gene expression data has remained a challenge for years. Ideally, a 
good ECG expression is one whose expression is independent of treatment condition 
and cell types. I demonstrated that the most commonly used ECGs, i.e., snoRNAs 
such as RNU6-1, vary in expression with 4-0HT treatment in MCF-7 and L Y2 cells. 
SNORD38D, 5SrRNA and SNORD48 were identified as good ECGs as they showed 
the least variation with 4-0HT treatment. They also exhibited a consistent pattern of 
expression in MCF-7 and L Y2 cells (Figure 4). My study shows the importance of 
the use of multiple ECGs to validate Q-PCR data. This is critical in miRNA gene 
analysis as the use of an inconsistent ECG leads to bias in results. 
Regulation of miRNA expression by the ER has been studied by very few 
groups [158,159,162,163]. As indicated by results in Chapter III, ICI studies 
demonstrated that the expression of miR-lOa, miR-21, miR-22, miR-200a, miR-221 
and miR-222 are ER-mediated in MCF-7 cells (Figure 5B and C). ICI treatment 
alone relieved the basal expression of these miRNAs, indicating that ER normally 
suppresses their expression in MCF-7 cells. There are reports of ERa being a target 
of the miR-22 and miR-2211222 family [231,234]. Increased expression of miR-
2211222 has also been reported in TAM- and fulvestrant- resistant breast cancer 
[283,369]. Higher expression of miR-22 11222 family and lower expression of ERa in 
L Y2 cells compared to MCF-7 cells agree with these reports. More studies are 
required to determine if ERa or ER~ are involved in the expression of the miRNAs 
identified in Chapter III. 
One important finding in my study is that there is a variable pattern of miRNA 
expression at different time points. 4-0HT increased the expression of miRNAs after 
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6 h of treatment (Figure 6). There was a corresponding increase in ERa protein levels 
after 6 h of 4-0HT treatment, further implying that the expression of miRNAs could 
be ER-mediated. 
Bioinformatic analysis identified 36 putative mRNA targets of the 12 miRNAs 
that were analyzed in Aim 1 (Figure 8). Expression of PDCD4, BCL2, CYPIBl, 
ESRI and ERBB3 was validated at the mRNA and protein level. Although there was 
agreement in the direction of expression of specific miRNAs and their putative 
targets, discrepancy was seen in the expression of PDCD4 and BCL2 protein in L Y2 
cells. Contrary to the expected increase in PDCD4 and BCL2 protein with lower 
miR-21 in LY2 cells, there was undetectable PDCD4 and BCL2 protein in LY2 cells. 
It is likely that these genes are under regulation by other miRNAs or other 
mechanisms such as epigenetic modification. Additionally, there are reports of 
phosphorylation of PDCD4 by Akt and S6Kl leading to its proteasomal degradation 
in HEK293 cells [370,371]. 
In Chapter IV, I report lower expression of miR-200 family members as cells 
progress towards endocrine-resistance (Figure 12). The role of miR-200 in drug 
resistance in ovarian, bladder and pancreatic cancer has been studied [323,353,355]; 
however, there are no reports of its role in antiestrogen-resistant breast cancer. An 
interesting discovery in Chapter IV of my dissertation is that restoring miR-200 
family members, miR-200b and miR-200c increased sensitivity of LY2 cells to 
inhibition by TAM and fulvestrant treatment (Figure 16A). These data imply that 
miR-200 contributes to endocrine-sensitivity of LY2 cells. However, the converse 
experiment (Figure 17) using antisense to miR-200b and miR-20Oc in MCF-7 cells 
did not make them resistant to TAM or fulvestrant. This implies that miR-200 is just 
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one of the players in the complex network of genes and pathways associated with 
endocrine resistance. 
Overexpression of miR-200 changed morphology of L Y2 cells from an 
elongated, mesenchymal to an epithelial appearance. This agrees with previous 
reports of the ability of miR-200 to reverse EMT in TNBC cells such as MDA-MB-
231 and BT-549 [205,345,347]. It was intriguing to find that LY2 cells did not 
undergo MET when transfected with miR-200a, miR-200b or miR-20Oc as there was 
no decrease in expression of the mesenchymal marker, vimentin, nor an increase in 
epithelial marker, E-cadherin. Perhaps there are other factors in addition to miR-200 
overexpression that are required to induce MET in L Y2 cells. Previous studies have 
shown that ERa inhibits EMT by suppressing the expression of transcription factors 
such as SLUG and Snail 1 [372-375]. LY2 cells have lower ERa when compared to 
MCF-7 cells (Figure 4F). Future studies could determine if restoration of ERa 
induces MET and restore sensitivity of L Y2 cells to treatment with 4-0HT and 
fulvestrant. 
Although most studies have focused on the role of miR-200 as a tumor 
suppressor, there are a few reports of miR-200 as an oncogene promoting mestastasis 
in breast cancer. Pro-metastatic effects of miR-200 family have been reported in an 
animal model of lung metastasis [366]. This would be a major drawback in the use of 
miR-200 as therapy to restore endocrine-responsiveness in cells. The expression of 
miR-200 family in tumor samples of patients resistant to TAM or fulvestrant therapy 
remains to be tested. This would give a clear understanding of the pattern of 
expression of this miRNA and for its use in therapy. 
Overall, this study contributes to better understanding of miRNAs that are 
dysregulated in endocrine-resistant breast cancer. By analyzing the miRNA signature 
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of breast cancer patients, it would be possible to determine if they are susceptible to 
developing resistance to these antiestrogens such as TAM and fulvestrant. This 
would be beneficial in a timely and effective treatment of patients with endocrine-
resistant breast cancer. My study on miR-200 family provides a novel link between 
miRNA regulation of EMT and endocrine-resistant breast cancer. Finally, my study 
demonstrates that miR-200 is a significant contributor of sensitivity to antiestrogen 
therapy. By elucidating the exact mechanism involved in regulation of miR-200 
expression, this could be an attractive target to restore TAM-responsiveness in cells. 
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APPENDIX 1: Differentially expressed miRNAs in MCF-7 estrogenffAM-




miR-lOa inhibits hoxd4 gene expression in breast cancer cells [376]. 
miR-lOa interacts with the 5' untranslated region of mRNAs encoding 
ribosomal proteins to enhance their translation and increases global protein 
expression [302]. 
In embryonic stem cells, RA induces binding of p65 to the miR-lOa 
promoter, leading to an increased in miR-lOa and enhanced miR-lOa 
expression suppresses HDAC4 expression [301]. 
miR-lOa is upregulated in bladder cancer and targets FGFR3 [377]. miR-I0a 
expression is increased by retinoic acid-induced NFlCB activation during 
smooth muscle cell (SMC) differentiation from mouse embryonic stem cells 
miR-lOa (ESCs) [301]. 
miR-21 is an oncomiR that is significantly up-regulated in all types of breast 
tumors [378] and in breast cancer cell lines [257]. miR-21 is overexpressed in 
all solid tumors (lung, breast, stomach, prostate, colon, and pancreatic) [258]. 
The role of miR-21 in breast cancer was recently reviewed [262]. miR-21 was 
significantly higher in ERa+ vs. ERa-, ErbB2 - vs. ErbB2 +, and in PR+ vs. 
PR- breast tumors [304]. Hypoxia increasedmiR-21 expression in MCF-7 
[379]. miR-21 in mammary gland was increased after 18 wks of Ez treatment 
of female ACI rats [157]. Both Ez and ICI decreased miR-21 in human 
endometrial stromal and glandular epithelial cells, but when combined, miR-21 
expression returned to basal [380]. E2 suppressed and ICI increased miR-21 in 
human myometrial smooth muscle cells [381]. E2 inhibited the ICI-induced 
increase in miR-21 in these cells [381]. Ez and Progesterone reduced miR-21 
expression on the uterus of ovex mice [382]. Angiotensin II increased miR-21 
expression, aldosterone secretion and proliferation m H295R human 
adrenocortical cells [383]. miR-21 expression was significantly reduced in 
tamoxifen-resistant MCF-7 cells [270]. Another group reported that Ez (4 h) 
increased miR-21 in MCF-7 cells [260]. Knockdown of miR-21 in ER-
negativelbasal- like MDA-MB-231 breast cancer cells decreased cell migration 
in vitro and the formation of tumors in the lungs of female nude mice after tail 
vein injection of the si-miR-21 transfected MDA-MB-231 cells [187]. miR-21 
was downregulated in MCF-7 cells with 48 h of treatment with 10 f..lg/ml 
Polyphenon-60 (green tea extract) [384]. miR-21 expression is induced by all-
miR-21 trans retinoic acid in ERa+ breast cancer cells [385]. 
MiR-22 was increased in rat mammary gland by 6 and 12 wks. of E2 treatment 
of female August Copenhagen Irish (ACI) rats [157]. MiR-22 was 
differentially expressed between patients with a short time to distant metastasis 
(TDM) (i.e., tumor aggressiveness) versus those with a long TDM [386]. 
miR-22 represses ERa expression by directly targeting the ERa mRNA 3' 
UTR [231]. 
miR-22 is a tumor suppressor that represses the c-Myc-binding protein 
MYCBP, a positive regulator of c-Myc [387]. 
miR-22 repressed the c-Myc-binding protein MYCBP, a positive regulator of 
c-Myc, which resulted in inhibition of growth of MCF-7 breast cancer cells 
[387]. 
miR-22 miR-22 is a tumor suppressor [387]. 
The miR-29 family is a tumor suppressor miRNA [388]. 
miR-29a expression was down-regulated in invasive lung and pancreatic cell 
lines and re-expression of miR-29a reduced the in vitro invasive ability of lung 





miR-29a was downregulated in prostate tumors [390]. 
miR-29 regulates CDK6 as well as oncogenes Tcl-14I and Mcl-I; cell growth 
and survival genes, YYI, p85, CDC42 and DNMT3; as well as natural killer 
and T-cell inhibitor B7-H3 [388]. 
miR-29a targets the 3'UTR of B7-H3, a surface immunomodulatory 
lycoprotein that inhibits natural killer cells and T cells, thus offering a 
nechanism by which loss of miR-29a plays a role in immune escape by solid 
llmors [391]. 
miR-29 is induced by Wnt signaling and in turn, the negative regulators of 
Wnt signaling, Dikkopf-I (Dkkl), Kremen2, and secreted frizzled related 
protein 2 (sFRP2), are direct targets of miR-29a in osteoblasts [392]. 
miR-29a was downregulated in human prostate cancer tumors - 42% [390]. 
miR-93 is in the tri-cistronic miR-106b cluster that expresses miR-106b, miR-
93 and miR-25. 
microRNAs mir-17, mir-106a, mir-106b, mir-93, mir-20, and mir-I8 are 
ancient paralogs [393]. 
expression of miR-93 was up-regulated in hypoxic trophoblasts [394]. 
miR-93 was among the rniRNAs determined to be the most stable miRNA 
normalizers in normal human tissues [286]. 
miR -93 was upregulated in HTL V -I-transformed human T-cell lines and 
primary peripheral blood mononuclear cells from adult T-cell leukemia 
patients [395]. 
miR-93 inhibits p21 expression, thus reducing a 'brake' on cell cycle 
progression [396] .. 
miR-93 is upregulated in squamous cell carcinoma (SCC), a type of nons mall 
cell lung carcinoma (NSCLC) [397]. 
miR-93 is upregulated in human hepatocellular carcinoma (HCC) compared to 
normal hepatic tissues [398]. 
miR-125b is a tumor suppressor miRNA in breast cancer [262]. 
miR-125b is consistently down-regulated in human breast cancer cell lines 
[257]. 
miR-125b was upregulated in Taxol-resistant breast cancer cell lines, 435TRa 
NA 435TRP compared to their parental MDA-MB-435 cell line [399]. 
Significantly higher in ErbB2- vs. ErbB2+ tumors [304]. 
Significantly higher in ERa+ than ERa- tumors [304]. 
Significantly higher in PR+ than PR- tumors [304]. 
miR-I25b inhibits ERBB2 and ERBB3 translation [201] 
miR-I25b expression was increased by hypoxia in MCF-7 cells [379]. 
miR-125b was downregulated in epithelial ovarian cancer [400] and m 
squamous cell carcinoma (SCC) of the tongue [401]. 
E2 down-regulated miR-125b in mouse splenic lymphocytes [402]. 
miR-125b was identified as a suppressor of the pathway activator Smoothened 
in cerebellar neuronal progenitor and tumor cells [403]. 
miR-125b is reduced in human hepatocellular carcinoma (HCC) [398] and 
high miR-I25b was correlated with good survival ofHCC patients [404]. 
miR-125b was downregulated in prostate tumors [390]. 
miR-125b is located at chromosome Ilq23-24, one of the regions most 
frequently deleted in breast, ovarian, and lung tumors [405]. 
miR-I25b repressed C-Raf protein expression in MDA-MB-453 breast cancer 
cells. 
miR-125b is upregulated in endometriosis [406]. 













miR -125b inhibits MUC 1 protein expression in MCF-7 breast cancer cells 
[408]. 
miR -125b confers paclitaxel resistance in breast cancer cells by suppressing 
Bak1expression [399]. 
miR-181a expression was reduced by E2 in MCF-7 cells [261]. 
miR-181a and miR-18lb are down-regulated in human gliomas and act as 
tumor suppressors which triggered growth inhibition, induced apoptosis and 
inhibited invasion in glioma cells [409]. 
Regulates oncogene TCLl in Chronic Lymphocytic Leukemia (CLL) [410] 
miR-181b was over-expressed in tumors compared to normal colorectal 
samples [411,412]. 
miR-181 b was downregulated in during retinoic acid-induced differentiation of 
human acute promyelocytic leukemia [413]. 
miR181b-1, miR-181c were down-regulated in prostate cancer [414]. 
miR-181a was upregulated in 4-0HT-resistant MCF-7 cells [270). 
Predicted targets [381]: hsa-miR181 a 9q33.3 ESR2, ABI1, ABI3BP, 
ADAM11, BMP3, BMPER, BMPR2, EGR1, EGR3, FGFR3, MMP14, 
MPP5, NCOA2, NEGR1, PAK4, PAK7, RUNX1, S100PBP, SMAD7, 
SOX5, SOX6, STC1, TGFBI, TGFBR1, TlMP3, TSC22D2 [381]. 
miR-181d was up-regulated greater than twofold in breast cancer compared 
with normal adjacent tissue [415]. 
miR-181 inhibits the translation of p27kip I (p27), a cell cycle inhibitor and 
tumor suppressor, in myeloid cell differentiation [416]. 
Antisense-microRNA oligonucleotides (AMOs) against miR-181a inhibited 
the growth of A549 human lung adenocarcinoma cells [417]. 
Overexpression of miR -181 a in A549 lung cancer cells sensitized the cells to 
the lethal action of cisplatin by stimulating Bax oligomerization and the 
activation of proapoptotic caspase [418]. 
miR-181a was reduced in human NSCLC tissues [419]. 
miR-181a inhibits the expression of a large number of zinc finger genes 
(ZNFs) by interacting with seed elements within the coding regions [420]. 
miR-200a correlated with ERa. status in human breast tumors [304]. miR-200a 
expression significantly up-regulated in all types of breast tumors compared to 
adjacent normal tissue [378]. 
Significantly> in ERa.+ than ERa.- human breast tumors (1) and PR+ than 
PR- breast tumors(1), miR-200a is expressed in MCF-7 and other epithelial 
breast cancer cell lines [203]. 
miR-200a was increased in colorectal cancer cell lines [421] and in epithelial 
ovarian cancer [400]. 
miR-200 expression was reduced in tamoxifen-resistant MCF-7 cells [270]. 
All five members of the microRNA-200 family (miR-200a, miR-200b, miR-
200c, miR-141 and miR-429) and miR-205 were markedly downregulated in 
cells that had undergone EMT in response to transforming growth factor 
(TGF)-beta [203] 
The miR-200 family inhibits expression of the related transcriptional 
repressors ZEB lIdeltaEFl and SIP11ZEB2 in epithelial cells and playa major 
role in preventing these factors from triggering epithelial to mesenchymal 
transition (EMT) [203]. 
However, miR-200 family members differentially regulate EGF-driven 
invasion, viability, apoptosis and cell cycle progression of breast cancer cells, 
with the miR-200bC/429 cluster showing stronger effects than the miR-
200al141 cluster [422]. 
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miR-200a expression is increased in ovarian tumors compared to normal ovary 
[423]. 
miR-200a expression was reduced in endometriosis [406]. 
miR-200a is upregulated in squamous cell carcinoma (SCC), a type of 
nonsmall cell lung carcinoma (NSCLC) [397]. 
E2 (4 h) increased miR-200a 2-fold in MCF-7 cells [260]. 
E2 (48 h) reduced miR-20Oc expression in MCF-7 cells [261]. 
miR-200a regulated ZEB I expression, thus regulating epithelial to 
mesenchymal transition (EMT) [424]. 
Likewise, there is a double negative feedback loop of miR-200ab and ZEB I, 
which regulates E-cadherin expression, in EMT [325]. 
miR-200c was highly expressed in MCF-7 cells with lower and more variable 
expression in MDA-MB-23I cells [425]. 
TCF8, also termed ZEB I, which is a key regulator of epithelial to 
mesenchymal transition (EMT) by repressing E-cadherin expression, was 
identified as the target of miR-200c in A549 lung cancer cells [324]. 
Recent studies have implicated a negative feedback loop of miR-200c and 
ZEB I in cancer cells including breast [205,322,323,325]. 
miR-200b and miR-200c are reduced in lymph node metastases of primary 
breast tumors [209]. 
Early studies reported that miR-205 expression was higher in ERaJPR-positive 
breast tumors and reduced in ErbB2-positive breast tumors [304]. 
Expression of miR-205 was restricted to the myoepithelial/basal cell 
compartment of normal mammary ducts and lobules and miR-205 expression 
was reduced or completely eliminated in matching tumor specimens [221]. 
miR-205 expression is reduced in breast cancer cells that had undergone EMT 
in response to transforming growth factor (TGF)-beta or to ectopic expression 
of the protein tyrosine phosphatase Pez [203]. 
miR-205 was downregulated in breast tumors and miR-205 directly targets 
HER3 and inhibits the activation of the downstream mediator Akt [426]. The 
reintroduction of miR-205 into SKBr3 breast cancer cells inhibited colony 
formation and increased inhibition by tyrosine-kinase inhibitors Gefitinib and 
Lapatinib, abrogating the HER3-mediated resistance and restoring a potent 
proapoptotic activity [426] 
MCF-7 and MDA-MB-23I express lower miR-205 than non-malignant MCF-
lOA cells [296]. Ectopic expression of miR-205 in MCF-7 cells significantly 
inhibited cell proliferation and overexpression of miR-205 inhibited MDA-
MB-231 cell invasion and metastasis to lung when injected into nude mice 
[296]. ErbB3 and vascular endothelial growth factor A (VEGF-A) are direct 
miR-205 targets for miR-205 [296]. 
Upregulated in 4-0HT-resistant [270] and Fulvestrant-resistant [272] MCF-7 
cells. 
Variably expressed in human breast tumors: highly expressed in some and 
completely absent in other specimens [221]. 
miR-221 is part of a gene cluster also expressing miR-222, a close homologue 
of miR-22 I [427]. Both miRNAs share an identical seed sequence [427]. 
Reduction of the p27Kipi tumor suppressor by miR-22I and miR-222 
promotes cancer cell proliferation [427]. 
MiR-221 and miR-222 both directly target the 3' untranslated regions of p27 
and p57 mRNAs [428]. 
miR-221 MiR-221 and miR-222 are elevated in ERa-negative breast cancer cells and 
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both directly target the 3' untranslated region of ESRI (ERa) and reduced ERa 
expression [295]. 
ERa inhibits miR-221 expression [234]. 
miR-221 was upregulated in Taxol-resistant breast cancer cell lines, 435TRa 
NA 435TRP compared to their parental MDA-MB-435 cell line [399]. 
miR-221 is down-regulated in prostate cancer [414] and regulates tumor 
suppressor ARHI expression [429]. 
miR-22I inhibits expression of p53 upregulated modulator of apoptosis 
(PUMA) in breast and lung cancer cells [430]. 
Upregulated in 4-0HT-resistant [270] and Fulvestrant-resistant [272] MCF-7 
cells. 
Variably expressed in human breast tumors: highly expressed in some and 
completely absent in other specimens [221]. 
miR-222 was upregulated in Taxol-resistant breast cancer cell lines, 435TRa 
NA 435TRP compared to their parental MDA-MB-435 cell line [399]. 
Overexpression of miR-222 in hepatocellular cancer activates AKT signaling 
[431 ]. 
Overexpression of miR-221 and 222 increased proliferation in ERa+ MCF-7 
breast cancer cells and reduced ERa protein levels [234]. ERa inhibits miR-
222 expression [234]. 
miR-222 inhibits expression of p53 upregulated modulator of apoptosis 
(PUMA) in breast and lung cancer cells [430]. 
Overexpression of miR-222 activates AKT signaling in hepatocellular 




mRNA gene targets of the indicated miRNAs differentially expressed in MCF-7 
versus L Y2 cells that were identified in Frasor et al. Cancer Research 2004 
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Frasor et a/ Cancer Res. 
2004 
8 h 4- 48 h 
microarray microarray in MCF-7 OHT* 40HT* 
mRNA MCF-7 + 4- LY2 + 4- expect 4 h 4- 24 h 4-
target miRNA OHT OHT mRNA OHT OHT 
hsa-miR- higher than 
SMPD1 10a -2 3 LY2 0.62* 0.49* 
hsa-miR-
EFNB2 10a 1.2 2.7 
hsa-miR-
GPR56 10a 1.4 2.3 
hsa-miR-
SDC1 10a 1.2 2 
hsa-miR-
LTBP1 10a 0.7 2.8 
hsa-miR- higher than 
B3GNTt 125b -2 1 LY2 1.4 2 
hsa-miR-
ERBB3 125b 0.61* 0.53* 
hsa-miR-
C14orf43 125b 2 1.5 
hsa-miR-
GGA2 125b 0.9 2.5 
hsa-miR-
NAT9 125b 0.9 0.5 
hsa-miR-
SDC1 125b 1.2 2 
hsa-miR-
BAK1 125b 0.49* 0.27* 
hsa-miR-
1L13RA1 125b 1.1 2.6 
hsa-miR-
ZNF185 125b 1 2.3 
hsa-miR- lower in 
PDCD4 200a 0.3 -3 MCF-7 0.7 0.5 
hsa-miR-
ETNK1 200a than in LY2 0.9 2 
hsa-miR-
RBL2 200a 0.54* 0.91 * 
hsa-miR-
BHLHB2 200a 1.6 3 
hsa-miR-
PTPRG 200a 1 4.3 
hsa-miR-
CDC2L6 200a 0.7 2.5 
hsa-miR-
1L13RA1 200a 1.1 2.6 
hsa-miR-
ZNF185 200a 1 2.3 
hsa-miR- lower in 
PDCD4 200b -0.1 -3 MCF-7 0.7 0.5 
hsa-miR-
B3GNTt 200b than in LY2 1.4 2 
hsa-miR-
RDX 200b 1 3 
hsa-miR-
EFNB2 200b 1.2 2.7 
l4l 
hsa-miR-
C14orf43 200b 2 1.5 
hsa-miR-
ABAT 200b 0.6 0.3 
hsa-miR-
CYP1Bl 200b 24.01* 4.24* 
hsa-miR-
GBEl 200b 0.8 2.5 
hsa-miR-
PKIA 200b 0.9 3.7 
tlsa-miR- lower in 
PDCD4 200c 0.3 -3 MCF-7 0.7 0.5 
hsa-miR-
B3GNTt 200c than in LY2 1.4 2 
hsa-miR-
RDX 200c 1 3 
hsa-miR-
ETNKl 200c 0.9 2 
hsa-miR-
EFNB2 200c 1.2 2.7 
hsa-miR-
ABAT 200c 0.6 0.3 
hsa-miR-
CYP1Bl 200c 24.01* 4.24* 
hsa-miR-
GBEl 200c 0.8 2.5 
hsa-miR- lower in 
PDCD4 21 -0.5 -0.9 MCF-7 0.7 0.5 
hsa-miR-
B3GNTt 21 than in LY2 1.4 2 
hsa-miR-
RDX 21 1 3 
hsa-miR-
ETNKl 21 0.9 2 
hsa-miR-
ABAT 21 0.6 0.3 
hsa-miR-
LTBPl 21 0.7 2.8 
hsa-miR-
PTPRG 21 1 4.3 
hsa-miR- higher in 
SMPDl 22 -0.4 1 MCF-7 0.62* 0.49* 
hsa-miR-
GALNT6 22 than in LY2 0.7 0.4 
hsa-miR-
ERBB3 22 0.61 * 0.53* 
hsa-miR-
TTC9 22 0.47* 0.31* 
hsa-miR-
RBL2 22 0.54* 0.91* 
hsa-miR-
YWHAZ 22 1.5 2 
hsa-miR-
1L13RAl 22 1.1 2.6 
hsa-miR- higher in 
ERBB3 222 -1.5 1.4 MCF-7 0.61* 0.53* 
hsa-miR-
EFNB2 222 than in LY2 1.2 2.7 
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hsa-miR-
CYP1B1 222 24.01* 4.24* 
hsa-miR-
MYLIP 222 0.7 0.4 
hsa-miR-
CDC2L6 222 0.7 2.5 
hsa-miR-
PRPS1 222 2.2 3 
hsa-miR- higher in 
SMPD1 29a -0.8 0.7 MCF-7 0.62* 0.49* 
hsa-miR-
RAB30 29a than in LY2 1.3 2.2 
hsa-miR-
C14orf43 29a 2 1.5 
hsa-miR- lower in 
CD44 93 0.6 -0.7 MCF-7 1 2 
hsa-miR-
SHANK2 93 than in LY2 0.8 2.5 
hsa-miR-
RAB30 93 1.3 2.2 
hsa-miR-
RDX 93 1 3 
hsa-miR-
ERBB3 93 0.61* 0.53* 
hsa-miR-
EFNB2 93 1.2 2.7 
hsa-miR-
TTC9 93 0.47* 0.31* 
hsa-miR-
C14orf43 93 2 1.5 
hsa-miR-
RBL2 93 0.54* 0.91* 
hsa-miR-
LASP1 93 1 2.5 
hsa-miR-
MSH2 93 0.8 2.1 
hsa-miR-
IER3 93 5 4.3 
hsa-miR-
CDC2L6 93 0.7 2.5 
hsa-miR-
PKIA 93 0.9 3.7 
hsa-miR-
YWHAZ 93 1.5 2 
has-miR- lower in 
DNAJC12 181a 1.6 0.01 MCF-7 0.5 0.3 
than in LY2 
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APPENDIX 3: Identity and location of genes shown in networks 1 and 2 
(Appendix 7) 
Symbol Entrez Gene Name Location 
Network1 
APC adenomatousQolyposis coli Nucleus 
ATPase, Ca++ transporting, cardiac muscle, 
ATP2A2 slow twitch 2 C~<mIasm 
BLZF1 basic leucine ziQI!er nuclear factor 1 C~<mIasm 
BPHL b~henyl h~drolase-like (serine I}ydrolasel C~<mIasm 
CASP3 ca~ase 3, ~~tosis-related cysteine .Qe.Qtidase C~<mIasm 
CCOC88B coiled-coil domain containirlR 88B Nucleus 
Extracellular 
CSF1 colon~ stimulatirlR factor 11macro.Qh<!9..~ S.Qace 
Extracellular 
CYR61 cysteine-rich, angiogenic inducer, 61 S.Qace 
OGAT1 diacylglycerol O-acyltransferase 1 GY!.<mIasm 
ONAJB5 OnaJ (Hsp40) homolog, subfamily B, member 5 unknown 
Extracellular 
FBLN5 fibulin 5 Space 
FMNL3 formin-like 3 unknown 
HOXA1 homeobox A1 Nucleus 
LMNA lamin AlC Nucleus 
MAP4 microtubule-associated Qrotein 4 C~<mIasm 
MIR10A (includes 
EG:406902) -- unknown 
MIR125B (human) -- unknown 
MIR200A (includes 
EG:406983) -- unknown 
MIR200B (includes 
EG:406984) -- unknown 
MIR205 (includes 
EG:406988) -- unknown 
MIR22 (includes 
EG:407004) -- unknown 
MIR222 (includes 
EG:407007) -- unknown 
MIR29A (includes 
EG:407021) -- unknown 
MIR93 (includes 
EG:407050) -- unknown 
v-myc myelocytomatosis viral oncogene 
MYC homolog (avian) Nucleus 
MYT1L myelin transcription factor 1-like Nucleus 
Extracellular 
NPTX1 neuronal pentraxin I Space 
PARP6 polyJAOP-riboseholymerase familY, member 6 unknown 
PLK2 polo-like kinase 2 Nucleus 
RAB10 RAB10, member RAS oncqflene family C-.rto~asm 
retinoic acid -- unknown 
RSF1 remodeling and spacing factor 1 Nucleus 
TOG -- Nucleus 
UNCX UNC homeobox unknown 




EstroQen Receptor unknown 
Extracellular 
IL6 interleukin 6 (interferon, beta 21 SRace 
MAP2 microtubule-associated protein 2 Cytoplasm 
Mapk unknown 





PGR progesterone receptor Nucleus 
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APPENDIX 4: ERa36 is not expressed in MCF-7 or LY2 cell lines. Whole cell 
extracts (30 )lg) indicated breast cancer cell lines (tamoxifen (TAM)- sensitive (S) or 
TAM-resistant (TAM-R) were immunoblotted for ERa, with 0-20 (SantaCruz 
Biotechnology). The membrane was stripped and reprobed for B-actin. ERa,36 lacks 
the AlB and F domains of ERa,66, but contains the DNA binding domain (DBD, C 
region), hinge region (D region), and most of the ligand binding domain (LBD, E 
region). It also has an extra, unique 27aa domain instead of the last 138 aa encoded by 
exons 7 and 8 of the hERa66 gene (Wang et al. PNAS 103: 9063-8, 2006). The 0-20 
antibody recognizes ERa, aa 281-360 in the DBD and hinge region and thus, it should 























APPENDIX 5: GAPDH levels in MCF-7 and LY2 are comparable. MCF-7 and 
L Y2 cells were treated with 10 nM estradiol (E2) or 100 nM 4-hydroxytamoxifen (4-
OHT) for 6 h. Quantitative real time PCR was employed to evaluate glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) expression because GAPDH is often used as a 
control gene for normalization of "test" mRNAs. Values are CT (cycle threshold) 





















APPENDIX 6: Results of Ingenuity Pathway Analysis. The top biological function 
and disease categories enriched with miRNAs in our dataset (Figure 3) are displayed 
along the x-axis. The y-axis displays the -(log) significance. Taller bars are more 
significant than shorter bars. Functions are listed from most significant to least and the 
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APPENDIX 7: Ingenuity Pathway Analysis (IPA) identified 2 networks of 
molecules that interact with the 12 miRNAs that are differentially expressed in 
MCF -7 versus L Y2 breast cancer cells. Core analysis identified 2 separate 
networks that are associated with our miRNA dataset (Figure 3). Analysis identified a 










Appendix 8: Overexpression of miR-200b or miR-200c in L Y2 cells transfected 
with pre-miR-200b or pre-miR-200c or negative control. L Y2 cells were 
transfected either with negative control or pre-miR-200a, pre-miR-200b or pre-miR-
200c. A. RNA was harvested after 3 days and Q-PCR performed to confirm 
overexpression of miR-200a, miR-200b or miR-200c. Values are the mean ± SEM of 
triplicate determinations. B. Image of L Y2 cells transfected with negative control, 
captured using a light microscope (20x magnification, 100 I..Im scale). 
3500 A • Neg control 
2500! I ~ miR-200a 
f 1:~~ : ~:::~~~~ 
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posters) 7th annual Brown Cancer Center Retreat, October 29, 2008. 
(Manavalan, T.T., Wickramasinghe, N.S., Li, Y., and Klinge, C.M. 
Regulation of miRNA expression by 4-hydroxytamoxifen in MCF-7 
breast cancer cells. Abstract #49) 
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RESEARCH EXPERIENCE 
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(Advisor: Dr. Carolyn M. Klinge) 
Identified miRNAs that are differentially expressed in antiestrogen-sensitive 
MCF-7 and anti-estrogen-resistant LY2 human breast cancer cells. Using 
bioinformatics, putative targets of the dysregulated miRNAs were identified. 
Correlated changes in miRNA expression with mRNA and protein changes of key 
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to antiestrogens, Tamoxifen and Fulvestrant. 
TECHNICAL SKILLS 
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Abstracts presented at National meetings: 
1. Manavalan, T.T and Klinge, C.M. Loss of miR-200 family of microRNAs 
confers resistance to tamoxifen in human breast cancer cells. (Abstract #1096), 
Abstracts of the 103rd annual meeting presented at the American Association 
for Cancer Research (AACR),Chicago, IL March 3 I-April 4, 2012 
2. Manavalan, T.T, Klinge, C.M., Datta, S., and Kalbfleisch, T.S. Differential 
Expression of MiRNAs In Antiestrogen-Sensitive MCF-7 versus 
Antiestrogen-Resistant L Y2 Breast Cancer Cells. (Abstract P3-68) Abstracts 
of the 93rd annual meeting of the Endocrine Society, Boston, MA, June 4-7, 
2011. 
Abstracts presented at local meetings: 
1. Barry, P., Riggs, KA., Manavalan, T.T., Patel, N.S., and Klinge, C.M. Role 
of estrogen receptor alpha isoform hERa46 in tamoxifen resistant breast 
cancer. (Abstract SMED 2) Research Louisville! University of Louisville 
School of Medicine, Louisville, KY, October 21, 2008. 
2. Manavalan, T.T., Wickramasinghe, N.S., Li, Y., and Klinge, C.M. 
Regulation of miRNA expression by 4-hydroxytamoxifen in MCF-7 breast 
cancer cells. (Abstract GRD-30) Research Louisville! University of 
Louisville School of Medicine, Louisville, KY, October 21, 2008. 
3. Wickramasinghe, N.S., Manavalan, T.T., Riggs, KA., Li, Y., and Klinge, 
C.M. Estradiol regulates miR-21 and its targets via ERalpha in MCF-7 breast 
cancer cells. (Abstract RA-53) Research Louisville! University of Louisville 
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4. Manavalan, T.T., Wickramasinghe, N.S., Li, Y., and Klinge, C.M. 
Regulation of miRNA expression by 4-hydroxytamoxifen in MCF-7 breast 
cancer cells. (Abstract# 49) i h annual Brown Cancer Center Retreat, October 
29,2008. 
5. Wickramasinghe, N.S., Manavalan, T.T., Riggs, KA., Li, Y., and Klinge, 
C.M. Estradiol downregulates miR-21 expression and miR-21 gene targets in 
MCF-7 breast cancer cells. Abstract 3051 presented at the 31 st annual San 
Antonio Breast Cancer Symposium, Dec. 10-14,2008. 
6. Wickramasinghe, N.S., Manavalan T.T., Dougherty, S. M., Yong Li, and 
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Klinge, C.M. Estradiol regulates miR-21 and its targets via ER-alpha in MCF-
7 breast cancer cells. (Abstract # 10) 11 th annual Institute for Molecular 
Diversity and Drug Design (IMD3) Symposium, March 10, 2009. *This 
poster was awarded the first place in the poster competition. 
7. Kapur, A., Manavalan, ToT., Wickramasinghe, N.S., Klinge, C.M. Regulation 
of protein targets of microRNAs by 4-hydroxytamoxifen in breast cancer cells. 
SROP poster presentations, University of Louisville School of Medicine, 
Louisville, KY, August, 2009. 
8. Manavalan ToTo, Wickramasinghe, N.S., Datta, S., Kalbfleisch, T., and 
Klinge, C.M. Differential expression of microRNAs in tamoxifen-resistant 
versus-sensitive human breast cancer cells. Abstract #13 presented as a poster 
at the 2009 Colloquium in Biochemistry and Molecular Biology (BMB), 
University of Louisville School of Medicine, August 21, 2009. (Honorable 
Mention (2nd of 17 posters selected for presentation by the BMB Research 
Committee). 
9. Manavalan, ToTo, Wickramasinghe, N.S., Datta, S., Kalbfleisch, T., Li, Y. 
and Klinge, C.M. Differential expression of microRNAs in tamoxifen-
sensitive versus - resistant human breast cancer cell lines. (Abstract GRD-54 ) 
Research Louisville! University of Louisville School of Medicine, Louisville, 
KY, October 15,2009. 
10. Manavalan, ToTo, Wickramasinghe, N.S., Datta, S., Kalbfleisch, T., Li, Y. 
and Klinge, C.M. Differential expression of microRNAs in tamoxifen-
sensitive versus - resistant human breast cancer cell lines. (Abstract #54) 8th 
Annual Retreat, James Graham Brown Cancer Center, Louisville, KY, 
November 6, 2009. 
11. Manavalan, ToTo, Wickramasinghe, N.S., Datta, S., Kalbfleisch, T., Li, Y. 
and Klinge, C.M. Differential expression of microRNAs in tamoxifen-
sensitive versus - resistant human breast cancer cell lines. (Abstract #18) 12th 
annual Institute for Molecular Diversity and Drug Design (IMD3) 
Symposium, IMD3 Symposium, March 9, 2010. 
12. Manavalan, ToTo, Teng, Y., Datta, S., Kalbfleisch, T.S., Li, Y. and Klinge, 
C.M. Differential expression of miRNAs in antiestrogen-sensitive MCF-7 
versus antiestrogen-resistant L Y2 breast cancer cells. (Abstract GRD-42) 
Research Louisville! University of Louisville School of Medicine, Louisville, 
KY, October 13, 2010. 
13. Manavalan, ToT., Teng, Y., Datta, S., Kalbfleisch, T.S., Li, Y. and Klinge, 
C.M. Differential expression of miRNAs in antiestrogen-sensitive MCF-7 
versus antiestrogen-resistant L Y2 breast cancer cells. (Abstract # 67) 9th 
annual Brown Cancer Center Retreat, Louisville, KY. November 5,2010. 
14. Manavalan, ToTo, Teng, Y., Datta, S., Kalbfleisch, T.S., Li, Y. and Klinge, 
C.M. Differential expression of miRNAs in antiestrogen-sensitive MCF-7 
versus antiestrogen-resistant L Y2 breast cancer cells. (Abstract #16) 13th 
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annual Institute for Molecular Diversity and Drug Design (IMD3) 
Symposium, March 8, 2011. 
15. Bell, J.D., Teng, Y., Manavalan, ToT., Kareparembil, S.A, Klinge, C.M. 
DHEA stimulates miR-21 expression in breast cancer cells. SROP poster 
presentation, University of Louisville School of Medicine, Louisville, KY, 
August 1,2011. 
16. Manavalan, ToTo, Teng, Y., Datta, S., Kalbfleisch, T.S., Li, Y. and Klinge, 
C.M. Differential expression of miRNAs in antiestrogen-sensitive MCF-7 
versus antiestrogen-resistant L Y2 breast cancer cells. Abstract #3 presented as 
a poster at the 2011 Colloquium in Biochemistry and Molecular Biology 
(BMB), University of Louisville, School of Medicine, August 26,2011. 
17. Manavalan, ToTo, Teng, Y., Datta, S., Kalbfleisch, T.S., Li, Y. and Klinge, 
C.M. Differential expression of miRNAs in antiestrogen-sensitive MCF-7 
versus antiestrogen-resistant L Y2 human breast cancer cells. (Abstract GRD-
53) Research Louisville! University of Louisville School of Medicine, 
Louisville, KY, October 11,2011. 
18. Manavalan, ToTo, Teng, Y., Datta, S., Kalbfleisch, T.S., Li, Y. and Klinge, 
C.M. Differential expression of miRNAs in antiestrogen-sensitive MCF-7 
versus antiestrogen-resistant L Y2 human breast cancer cells. (Abstract #84) 
lOth annual Brown Cancer Center Retreat, Louisville, KY. October 28, 20 II. 
19. Manavalan, ToT and Klinge, C.M. Loss of miR-200 family of microRNAs 
confers resistance to tamoxifen in human breast cancer cells. (Abstract #17), 
14th Annual IMD3 (Institute for Molecular Diversity and Drug Design) 
Symposium, March 13th, 2012. 
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